US ERA ARCHIVE DOCUMENT



# UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

# **MEMORANDUM**

DATE: 11/20/97

SUBJECT: PP#8E3574; Human Health Risk Assessment for Terbufos in/on

Coffee (Tolerances Expire 12/15/97).

DP Barcode: D240347 PRAT Case#: 260426 Submission #: S532580

Caswell#: 131A Chemical#: 105001 Trade Name: None

EPA Reg#:

105001 Class: Insecticide
None 40 CFR: 180.352
None (Product not registered in the US.)

TO: T. Levine/M. Mautz PM Team 04
Insecticide Branch/RD (7505C)

FROM: William D. Wassell, Chemist

Pamela M. Hurley, Toxicologist

RAB2/HED (7509C)

THRU: Richard Loranger, Branch Senior Scientist

RAB2/HED (7509C) R. Loranger

# INTRODUCTION

Tolerances are established (40 CFR 180.352(a)) for residues of the insecticide terbufos (S-[[(1,1-dimethylethyl)thio]methyl]0,0-diethyl phosphorodithioate) and its cholinesterase-inhibiting metabolites (terbufoxon sulfoxide, and terbufoxon sulfone) in or on the following raw agricultural commodities (RAC's):

RAC		Tolerance (ppm)
Bananas	٠	. 0.025
Beets, Sugar (Roots)		. 0.05
Beets, Sugar, (tops)		. 0.1
Corn, Field, Fodder		. 0.5
Corn, Field, Forage		. 0.5
Corn, Pop, Forage .	٠.•	. 0.5
Corn, Grain	•	. 0.05

61

Corn, Sw	eec CWHR)			0.05
Corn, Sw	eet, Forage		•	0.5
Corn, Sw	eet, Fodder		٠	0.5
Sorghum,	Fodder			0.5
Sorghum,	Forage	•		0.5
	Grain			

A tolerance with an expiration date of 12/15/97 is established (40 CFR §180.352(b)) for residues of terbufos and its cholinesterase-inhibiting metabolites in or on coffee, beans at 0.05 ppm. There are no U.S. products registered for use on coffee.

The HED Chapter of the Reregistration Eligibility Decision Document (RED) for Terbufos has been issued (10/17/95, D.L. McCall). The HED Chapter of the RED did not address FQPA-specific concerns. The conclusions drawn in the HED Chapter of the RED are applicable to the expiring tolerance on coffee with the exception of sections pertaining to special sensitivity of infants and children, the reference dose (RfD) and risk estimates. We note: the RED recommended that tolerance Levels for sorghum, fodder and sorghum, forage be increased to 1.0 ppm from 0.5 ppm.

The molecular structure of terbufos is:

$$S$$
 |  $(C_2H_5O)_2 -P-S-CH_2-S-C(CH_3)_3$ 

·Terbufos

#### I. EXECUTIVE SUMMARY

RAB2's estimates of chronic risk (water only) based upon EFED's highest estimates for terbufos in water exceed HED's level of concern. RAB2's estimates of chronic risk (food only) for the population subgroups of infants and children based upon tolerance level residues and percent crop treated data for terbufos are above HED's level of concern. The chronic risk (food only) estimate for the population subgroup U.S. Population is at an acceptable level (33% of the RfD).

We note: If anticipated residue estimates were utilized in place of tolerance level residues in the DRES analysis, the exposure estimates would decrease. RAB2 has not attempted to more highly refine our chronic risk estimates for terbufos because highly refined acute risk estimates for this active ingredient (ai) are above our levels of concern.

RAB2's estimates of acute risk from water only based upon EFED's highest estimates for terbufos in water exceed HED's level of concern. RAB2's estimates of acute risk based upon tolerance level residues from food only for terbufos are above HED's level of concern.

The registrant's acute risk estimates (food only and food plus water) for all population subgroups except Women (13 yrs plus) based upon anticipated residues and Monte Carlo analysis are above HED's level of concern. We Note: The registrant's analysis of acute risk was not extensively reviewed in conjunction with current action.

An occupational exposure analysis is not required for this use on coffee as this use is not registered for domestic use. A residential exposure analysis is not required as terbufos is not registered for residential/homeowner use.

As acute risk estimates for most population subgroups exceed our levels of concern, HED recommends against the extension of the time-limited tolerance for residues of terbufos and its cholinesterase-inhibiting metabolites in or on coffee.

# II. SCIENCE ASSESSMENT

# 1. Dose Response Assessment

# a. Special Sensitivity to Infants and Children

On September 8, 1997, The Health Effects Division's Hazard Identification Assessment Review Committee determined that there are sufficient data available to adequately assess the potential for toxicity to young animals following pre- and/or post-natal exposure to terbufos. These include acceptable developmental toxicity studies in rats and rabbits as well as a 2-generation reproduction study in rats. In addition, no treatment-related effects in the reproductive organs were seen in subchronic and chronic studies conducted in mice, rats and dogs. The developmental toxicity studies in rats and rabbits showed no evidence of additional sensitivity to young rats or rabbits following pre- or postnatal exposure to terbufos and comparable NOELs were established for adults and offspring. Based upon a weight-of-the-evidence consideration of the data base, the Committee determined that a developmental neurotoxicity study in rats is not required.

For acute dietary risk assessment, the Committee determined that the 10x factor to account for enhanced sensitivity of infants and children (as

required by FQPA) should be reduced to 3x. Therefore, a Margin of Exposure of 300 is required to ensure protection of these population subgroups from acute exposure to terbufos because:

- (1) Lack of acute and subchronic neurotoxicity studies. Data on cholinesterase inhibition, FOB, and histopathology on the central and peripheral nervous system are not available for evaluation after a single exposure to terbufos.
- (2) Lack of evaluation of a critical endpoint (i.e., measurement of cholinesterase activity) in the developmental or reproduction studies which would have yielded a comparison of this endpoint in adults and offsprings.

For chronic dietary risk assessment, the Committee determined that the 10x factor to account for enhanced sensitivity of infants and children (as required by FQPA) should be reduced to 3x for a total UF of 300 (i.e., 10 for inter-species variation x 10 for intra-species variation x 3 for FQPA) to ensure protection of these population subgroups from chronic exposure to terbufos. The UF of 300 is required because of the:

- (1) Lack of acute and subchronic neurotoxicity studies. Data on cholinesterase inhibition, FOB, and histopathology on the central and peripheral nervous system are not available for evaluation after repeated exposures to terbufos.
- (2) Lack of an evaluation of a critical endpoint (i.e., measurement of cholinesterase activity) in the developmental or reproduction studies which would have yielded a comparison of this endpoint in adults and offsprings.

Cholinesterase (ChE) activity was not measured in either the adults or the offspring in the developmental toxicity studies. In the reproduction study, ChE activity was measured only in adults and not in the pups. Therefore, no comparisons could be made for this endpoint between adults and offspring. In addition, data gaps exist for acute and subchronic neurotoxicity studies.

# b. Reference Dose (RfD)

The endpoint for chronic dietary risk assessment is based on plasma cholinesterase inhibition observed at 0.015 mg/kg/day (LOEL) in a 28-day oral study in dogs. The NOEL was 0.005 mg/kg/day. The study was performed at dose levels of 0, 0.00125, 0.005 or 0.015 mg/kg/day given orally by capsule. A UF of 100 applied to the NOEL for all population subgroups other than infants and children; 10x each for inter and intra species variability. Thus, an RfD of 0.00005 mg/kg/day was derived for

# all population subgroups other than infants and children.

For infants and children, the additional UF of 10 (required by FQPA) beyond the ones for inter and intra species variability is reduced to 3. For infants and children, an additional uncertainty factor of 3 will be used with the RfD value for risk assessment of these population subgroups.

The toxicological endpoints for terbufos are summarized in Table 1.

TABLE 1. Summary of Toxicological Endpoints for Terbufos

Exposure Duration	Exposure Route	Endpoint and Toxicological Effect
Acute	Dietary	NOEL: 0.005 mg/kg/day (inhibition of plasma cholinesterase activity at 0.015 mg/kg/day). MOE: 300 for infants and children population subgroups. MOE: 100 for all other population subgroups.
Short-Term (1-7 days) Occupational/Residential	Dermal	Dermal: NOEL: 0.005 mg/kg/day with 100% dermal absorption (inhibition of plasma cholinesterase activity at 0.015 mg/kg/day).
Intermediate-Term (one week to several months) Occupational/Residential	Dermal	Dermal: NOEL: 0.005 mg/kg/day with 100% dermal absorption (inhibition of plasma cholinesterase activity at 0.015 mg/kg/day).
[All time periods]	[Inhalation]	Inhalation:NOEL: 0.01 μg/L (significant decreases in plasma, RBC and brain cholinesterase at 0.04 μg/L).

Exposure Duration	Exposure Route	Endpoint and Toxicological Effect
Cancer	Dietary/Dermal/Inhalation	Classified as a group E: no evidence of carcinogenicity by the oral exposure route.
Chronic (non-cancer)	Dietary	RFD: 0.00005 mg/kg/day (NOEL of 0.005 mg/kg/day with UF of 100; plasma cholinesterase inhibition at 0.015 mg/kg/day) for population subgroups other than infants and children. For infants and children, an additional uncertainty factor of 3 will be used with the RfD for assessment of risk for these subgroups.

We Note: An occupational exposure analysis is not required for this use on coffee as this use is not registered for domestic use. A residential exposure analysis is not required as terbufos is not registered for residential/homeowner use.

# 2. Dietary Exposure and Risk Assessment/Characterization

# a. Dietary Exposure (Food Sources)

The RACs (Raw Agricultural Commodities) and tolerances, used in the dietary risk assessment, were derived from 40 CFR 180.352 and the Tolerance Index System:

Commodity1:	Tolerance: (ppm)
Bananas	0.025
Coffee	0.05
Beets, Sugar (Roots)	. 0.05
Corn, Grain	0.05
Corn, Sweet	0.05

Tolerances for residues of terbufos and its chlinesterase-inhibiting

metabolites are pending in/on soybean grain (Memo, 2/17/89, F. Toghrol, PP#2F2608, DEB# 4466); peanut nutmeat, shells and oil (Memo, 5/20/88, W.T. Chin, PP#4F2996/8H5549, RCB # 3100); mustard and rape seed (Memo, 7/30/90, R.W. Cook, PP#3F2926).

# b. Dietary Exposure (Drinking Water Source)

There is no Maximum Contaminant Level (MCL) established for residues of terbufos in drinking water. Health Advisory (HA) levels have been established for residues of terbufos in drinking water based upon an RfD of 0.00013 mg/kg/day with a drinking water equivalent level of 0.005 mg/L. They are as follows:

Lifetime level of 0.009 mg/L Long-term level of 0.005 mg/L

This information was furnished by the EPA Safe Drinking Water Hotline (1-800-426-4791) on 10/06/97.

EFED has provided estimates of terbufos levels in ground and surface water (Memo, J. Breithaupt, 9/30/97). The highest residue estimate for chronic risk assessment was 8.7 ug/L (for ground water). This estimate was from a ground water monitoring study. The highest residue estimate for purposes of acute risk assessment was 21.7 ug/L (for surface water). This estimate was from simulation utilizing PRZM 2.3 (Pesticide Root Zone Model). PRZM 2.3 simulates the transport of a pesticide off agricultural fields and is considered to overestimate actual drinking water concentrations for the active ingredient. We further note that 32 fish kills have been attributed to terbufos use. In order for fish kills to occur surface water concentrations were estimated to range from 0.77 to 20 ug/L. This concentration range is within the concentration range predicted by PRZM 2.3.

Current HED policy is to calculate a "Level of Concern" (LOC) for the active ingredient in water and compare this level to the maximum estimate for residues of the active ingredient in surface and/or ground water. The LOC for drinking water is defined as the concentration level at which the human health risk exceeds HED's level of concern. HED was unable to calculate a level of concern of terbufos in drinking water as our risk estimates for dietary exposure (food only) exceed HED's level of concern based upon both the chronic and acute dietary toxicological endpoints.

# For chronic exposure based upon the highest estimate for terbufos in water:

The highest EFED estimate for terbufos in water is 8.7 ug/L (for

residues in ground water). This estimate was based on the proposed use rate for grain sorghum and/or sugar beets and SCI-GROW. Assuming no dietary exposure (food only) and estimating the risk level based upon 8.7 ug/L in water, the level of risk (from drinking water only) was calculated to occupy as much as 5220% of the RfD for children, 487% of the RfD for adult males and 580% of the RfD for adult females.

# For acute exposure based upon the highest estimate for terbufos in water:

We note: Acceptable MOE's for children are ≥300 and acceptable MOE's for adults are ≥100.

The highest EFED estimate for residues of terbufos in water is 21.7 ug/L for residues in surface water. This estimate was based on the label directions of grain sorghum and PRZM 2.3. Assuming no dietary exposure (food only) and estimating the risk level based upon 21.7 ug/L in water, the level of risk from drinking water only was calculated to have an MOE of 0.005 for children, an MOE of 8.6 for adult males and an MOE of 6.9 for adult females.

RAB2 concludes there is a concern for residues of terbufos in drinking water based upon both chronic and acute toxicological endpoints. This conclusion is based upon EFED's estimates for residues in ground and surface water.

# c. Dietary Risk Assessment and Characterization

### i. Chronic Risk

The endpoint for chronic dietary risk assessment is based on plasma cholinesterase inhibition observed at 0.015 mg/kg/day (LOEL) in a 28-day oral study in dogs. The NOEL was 0.005 mg/kg/day. A UF of 100 applied to the NOEL for all population subgroups other than infants and children. For infants and children, the additional UF of 10 (required by FQPA) is reduced to 3. Thus, for this population subgroup, the total UF is 300. Thus, an RfD of 0.00005 mg/kg/day was derived for all population subgroups other than infants and children. For infants and children, an additional uncertainty factor of 3 will be used with the RfD value for assessment of risk for these groups.

Assuming tolerance level residues and 100% of the crop treated, the total TMRC (Theoretical Maximum Residue Contributions) exposure for dietary exposure from terbufos for the U.S. population from established tolerances is estimated as being 0.000055 mg/kg bodyweight per day and

the risk estimate is 110% of the Reference Dose (RfD). The subgroups with the highest estimated dietary TMRC exposures/risks are as follows:

Subgroup:	TMRC (mg/kg/day)	Percent RfD
U.S. Population	0.000055	110%
Nursing Infants	0.000051	310%
Non-nursing Infants (< 1 Year Old)	0.00012	696%
Children (1 to 6 Years Old)	0.00013	790%
Children (7 to 12 Years Old)	0.000089	530%

Adjustments of the TMRC exposure, by inclusion of percent crop treated data for field corn; sweet corn; sorghum; and sugar beets, roots in the DRES analysis produced ARCs (Anticipated Residue Contributions) for the same subgroups and substantially lowered the estimates of chronic dietary exposure to terbufos. The total dietary ARC exposure of the U.S. population is estimated to be 0.000016 mg/kg bodyweight per day and the risk estimate was 33% of the RfD. The subgroups with the highest estimated dietary total ARC exposures/risks are as follows:

Subgroup:	ARC (mg/kg/day)	Percent RfD
Nursing Infants	0.000027	160%
Non-nursing Infants (< 1 Year Old)	0.000040	240%
Children (1 to 6 Years Old)	0.000039	230%
Children (7 to 12 Years Old)	0.000022	130%

The raw agricultural commodities which contribute the most ARC exposure/risk for U.S. populations from dietary terbufos are bananas, corn (all), and beets (sugar).

RAB2 concludes the chronic risk estimates (food only) utilizing percent crop treated data and tolerance level residues for terbufos exceed HED's level of concern. We note: If anticipated residue estimates were utilized in place of tolerance level residues in the DRES analysis, the exposure estimates would decrease. RAB2 has not attempted to more highly refine our chronic risk estimates for terbufos because highly refined acute risk estimates for this ai are above our levels of concern.

# iii. Acute Dietary Risk

The acute dietary endpoint (one day) is based on the NOEL for plasma cholinesterase inhibition (0.005 mg/kg/day) in dogs. An MOE of  $\geq 100$  is considered acceptable for all population subgroups other than those for infants and children. For infants and children, the 10x factor to account for enhanced sensitivity of infants and children (as required by FQPA) has been reduced to 3x. Therefore, a Margin of Exposure of  $\geq 300$  is required to ensure protection of this population from acute exposure to terbufos

Acute dietary exposure analysis estimates the distribution of single-day exposures for the U.S. population and certain subgroups. The analysis evaluates individual food consumption as reported by respondents in the 1977-78 Nationwide Food Consumption Survey and accumulates exposure to terbufos for each food commodity which has a terbufos tolerance. As such, the exposure estimate is a maximal estimate because it assumes that terbufos residues are present at the maximum legal limit in the entirety of the commodities in which they can occur.

The Margin of Exposure (MOE) for acute dietary risk was calculated for the U.S. population and for four population subgroups. The calculated MOEs using a NOEL of 0.005 mg/kg bodyweight/day were:

Population Groups:	Percentile Pop.:	MOE:
U.S. population	96th	25
Infants (<1 Year Old)	96th	10
Children (1-6 Years Old)	98th	10
Females (≥13 Years Old)	93rd	50
Males (≥ 13 Years Old)	91st	50

Margin of Exposure (MOE) =  $\frac{NOEL}{exposure}$ 

RAB2 concludes our acute risk estimates (food only) for terbufos are above HED's level of concern of all population subgroups.

The petitioner has submitted the results (MRID No. 444070-01) of a Monte Carlo analysis in order to present a more realistic estimate of exposure. This study was not extensively reviewed by RAB2 in conjunction with the current action. The analysis was performed by Novigen Sciences Inc. The introduction of this report states that utilizing EPA's Tier 3 methodology (Monte Carlo) for acute exposure Margin's of Exposure (MOE's) up to the 99th percentile of exposure (food

only) were approximately 100 for all population subgroups.

HED requires the MOE's up to the 99.9th percentile to be at an acceptable exposure level. For terbufos, the acceptable MOE's for adult population subgroups are to be ≥100. For children population subgroups, the acceptable MOE's are to be ≥300.

MOE's at the 99.9th percentile are contained in Appendix 4 of the registrant's report. The MOE's at the 99.9th percentile (food only and food plus water) for various population subgroups are as follows:

Population Subgroup	MOE (food only)	MOE (food + water)
U.S. Population	83	82
Children (1 to 6 yrs)	43	43
Children (7 to 12 yrs)	82	83
All Infants	53	51
Women (13 yrs +)	151	153

RAB2 concludes the registrant's acute risk estimates (food only and food plus water) for all population subgroups except Women (13 yrs plus) are above HED's level of concern.

# 3. Occupational and Residential Exposure and Risk Assessment/Characterization

An occupational exposure analysis is not required for this use on coffee as this use is not registered for domestic use. A residential exposure analysis is not required as terbufos is not registered for residential/homeowner use.

# 4. Aggregate Exposure and Risk Assessment/Characterization

# a. Chronic Aggregate Exposure and Risk

RAB2's estimates of chronic risk (water only) based upon EFED's highest estimates for terbufos in water exceed HED's level of concern. RAB2's estimates of chronic risk (food only) for the population subgroups of infants and children based upon tolerance level residues and percent crop treated data for terbufos are above HED's level of concern. Therefore, estimates of chronic aggregate risk (food plus water) also exceed HED's level of concern for these populations. The chronic risk

(food only) estimate for the population subgroup U.S. Population is at an acceptable level (33% of the RfD).

We note: If anticipated residue estimates were utilized in place of tolerance level residues in the DRES analysis, the exposure estimates would decrease. RAB2 has not attempted to more highly refine our chronic risk estimates for terbufos because highly refined acute risk estimates for this ai are above our levels of concern.

# b. Acute Aggregate Exposure and Risk

RAB2's estimates of acute risk (water only) based upon EFED's highest estimates for terbufos in water exceed HED's level of concern. RAB2's estimates of acute risk (food only) based upon tolerance level residues for terbufos are above HED's level of concern.

The registrant's acute aggregate risk estimates (food plus water) based upon anticipated residue estimates and Monte Carlo analysis for all population subgroups except Women (13 yrs plus) are above HED's level of concern. We Note: The registrant's analysis of acute risk was not extensively reviewed.

As most acute risk estimates exceed our levels of concern, HED recommends against the extension of the time-limited tolerance for residues of terbufos and its cholinesterase-inhibiting metabolites in or on coffee.

# 5. Other Food Quality Protection Act Considerations

# a. Cumulative Risk (standard language)

Terbufos is a member of the organophosphate class of insecticides. Some of the other members of this class include malathion, trichlorfon, naled, mevinphos, acephate and methyl and ethyl parathion (G.W. Ware, Fundamentals of Pesticides, 3rd edition, 1991).

Section 408(b)(2)(D)(v) of the Food Quality Protection Act of 1996 requires that, when considering whether to establish, modify, or revoke a tolerance, the Agency consider "available information" concerning the cumulative effects of a particular pesticide's residues and "other substances that have a common mechanism of toxicity". The Agency believes that "available information" in this context might include not only toxicity, chemistry, and exposure data, but also scientific policies and methodologies for understanding common mechanisms of toxicity and conducting cumulative risk assessments. For most pesticides, although the Agency has some information in its files that may turn out to be helpful in eventually determining whether a pesticide shares a common mechanism of toxicity with any other substances, EPA

does not at this time have the methodologies to resolve the complex scientific issues concerning common mechanism of toxicity in a meaningful way. EPA has begun a pilot process to study this issue further through the examination of particular classes of pesticides. The Agency hopes that the results of this pilot process will increase the Agency's scientific understanding of this question such that EPA will be able to develop and apply scientific principles for better determining which chemicals have a common mechanism of toxicity and evaluating the cumulative effects of such chemicals. The Agency anticipates, however, that even as its understanding of the science of common mechanisms increases, decisions on specific classes of chemicals will be heavily dependent on chemical-specific data, much of which may not be presently available.

Although at present the Agency does not know how to apply the information in its files concerning common mechanism issues to most risk assessments, there are pesticides as to which the common mechanism issues can be resolved. These pesticides include pesticides that are toxicologically dissimilar to existing chemical substances (in which case the Agency can conclude that it is unlikely that a pesticide shares a common mechanism of activity with other substances) and pesticides that produce a common toxic metabolite (in which case common mechanism of activity will be assumed).

EPA does not have, at this time, available data to determine whether terbufos has a common mechanism of toxicity with other substances or how to include this pesticide in a cumulative risk assessment. For the purposes of this tolerance action, therefore, EPA has not assumed that terbufos has a common mechanism of toxicity with other substances.

# b. Endocrine disruption

EPA is required to develop a screening program to determine whether certain substances (including all pesticides and inerts) "may have an effect in humans that is similar to an effect produced by a naturally occurring estrogen, or such other endocrine effect..." The Agency is currently working with interested stakeholders, including other government agencies, public interest groups, industry and research scientists in developing a screening and testing program and a priority setting scheme to implement this program. Congress has allowed 3 years from the passage of FQPA (August 3, 1999) to implement this program. At that time, EPA may require further testing of this active ingredient and end use products for endocrine disrupter effects.

Attachments (4): 1) The HED Chapter of the Reregistration Eligibility Decision Document (RED) for Prometryn (3/16/95 J.C.

Redden, Case #0467).

- 2) Chronic DRES Analyses (9/17/97).
- 3) Acute Dietary Analyses (excluding coffee) (3/22/95).
- 4) Acute Dietary Analyses (coffee only) (3/22/95).

cc with Attachments: W.D. Wassell (RAB2), P. Hurley (RAB2), PP#8E3574, RAB2, B. Steinwand (CEB1)

cc without Attachments: Caswell File, J. Breithaupt (EFED, 7507C), W.Hazel (RRB1, 7509C), L. Nisenson (SRRD, 7508C).

RDI: RAB2: 11/18/97.

Disk: WDW-10, File: Terbufos.2

# October 17, 1995 MEMORANDUM

SUBJECT: The Revised HED Chapter of the Reregistration Eligibility

Decision Document (RED) for Terbufos, Case #0109

(PCCode 105001)

FROM: Deborah L. McCall

Risk Characterization and Analysis Branch

Health Effects Division (7509C)

THRU: Karen Whitby, Ph.D., Acting Chief

Risk Characterization and Analysis Branch

Health Effects Division (7509C)

and

Stephanie Irene, Ph.D., Acting Director /s/

Health Effects Division (7509C)

TO: Jack Housenger, Chief

Special Review Branch

Special Review and Reregistration Division (7508W)

Attached is the Revised Human Health Assessment for the Terbufos Reregistration Eligibility Decision Document. This assessment completely replaces the previously issued chapter in 1994. The revised chapter includes the original assessments from P. McLauglin (TOX II), J. Bazuin (SAB), C. Swartz (CBRS) plus the revised Occupational Exposure Assessment from Al Nielsen (OREB, see Attachment I).

Terbufos is an organophosphate insecticide/nematicide applied as a granular formulation by soil incorporation, during planting or post-emergence of terrestrial food and feed crops. Tolerances for residues of terbufos and its metabolites in/on raw agricultural commodities are established in 40 CFR 180.352. A Reregistration

Standard for terbufos was issued in September 1988.

HED considers terbufos to be of concern for health effects from acute dietary exposure, particularly for infants and children. Margins of exposure (MOEs) are 25 for the general population and 13 for infants and children.

cc: A. Levy

A. Nielsen

# Attachments:

Revised Occupational/Residential Exposure Assessment Ι

(with attachments) Amy Farrell cc:mail

(without attachments) Alan Levy cc:mail

Al Nielson

Christina Swartz

Beth Doyle

(with attachments) (2) Marvin Hawkins cc:

(without attachments) **RCAB** cc:

disk (with attachments) **RCAB** 

#### REVISED HUMAN HEALTH ASSESSMENT OF TERBUFOS

The Health Effects Division has conducted a thorough review of the scientific data base for terbufos, to support the reregistration eligibility decision for this pesticide. The findings are summarized below.

# A. PRODUCT CHEMISTRY ASSESSMENT

# 1. Identification of the Active Ingredient

Terbufos (S-[[(1,1-dimethylethyl)thio]methyl]O,O-diethyl phosphorodithioate) is a restricted use organophosphate insecticide and nematicide. The molecular structure of terbufos is:

$$S$$
  $\|$   $(C_2H_5O)_2 -P-S-CH_2-S-C(CH_3)_3$ 

Terbufos

Other identifying characteristics and codes are:

Physical Properties: Clear, slightly brown liquid

Empirical Formula: C<sub>9</sub>H<sub>21</sub>O<sub>2</sub>PS<sub>3</sub>,

Molecular Weight: 288.4

CAS Registry No.: 13071-79-9

Shaughnessy No.: 105001

Melting Point: -15°C

# 2. Other Product Chemistry Issues

There is one manufacturing-use product for terbufos, referred to as the 85% technical (T) (EPA Reg. No. 241-241). All pertinent data requirements for the terbufos 85% MP/T (EPA Reg. No. 241-241) have been satisfied by the American Cyanamid in recent submissions (MRID Nos. 43147500, 43147501, 43147502 and

43147503).

#### B. HUMAN HEALTH ASSESSMENT

# I. Toxicology Assessment

The toxicological data base on terbufos is adequate and will support reregistration eligibility.

# a. Acute Toxicity

The acute toxicity values and categories for terbufos are summarized in the Table 1 below.

TABLE 1: Acute Toxicity (technical)

TEST	RESULTS	CATEGORY
Oral LD <sub>50</sub> - rat	LD <sub>50</sub> = Males 1.6-4.5; Females 1.3-9.0 mg/kg	I
Oral LD <sub>50</sub> - mouse	$LD_{50}$ = Males 3.5; Females 5.0-9.2 mg/kg	, I
Oral LD <sub>50</sub> - dog	LD <sub>50</sub> = Males 4.5; Females 6.3 mg/kg	Ι
Inhalation LC <sub>50</sub>	data gap	
Dermal LD <sub>50</sub> - rabbit	$LD_{50}$ = Males 0.8-1.1; Females 0.93 mg/kg	I
Eye irritation - rabbit	100% deaths in 24 hours	
Dermal irritation - rabbit	100% deaths in 24 hours	

Terbufos has a high degree of acute toxicity when tested by various routes of administration using concentrations ranging from 86.0% to 97.7%. The  $LD_{50}$  values for terbufos in acute oral rat studies ranged from 1.6 to 4.5 mg/kg in males and 1.3 to 9.0 mg/kg in females (guideline 81-1). Similar oral  $LD_{50}$  values were obtained with terbufos in mice and dogs (MRID 00044957, 00037467, 00037471, 00035121). In several additional acute tests in mice,

the oral  $LD_{50}$  values for phosphorus-containing and nonphosphorus-containing metabolites of terbufos ranged from 1.1 to 14.0 mg/kg (Parkin, 1973).

The LD<sub>50</sub> for terbufos from acute dermal rabbit studies ranged from 0.8 to 1.1 mg/kg in males and was 0.93 mg/kg in females (guideline 81-2; MRID(s): 00044957, 00037467, 00144805). There is no acute inhalation study available that is applicable to the guidelines. Confirmatory information from a two-week inhalation study in rats indicates mortality (2/10 females) and cholinesterase activity depression were found at a concentration of 0.0394 mg/m³ (MRID 00258710). An acute inhalation study is required; however, the two-week study may be considered confirmatory because testing of end-use products addresses labeling concerns.

In primary eye and primary dermal irritation studies in rabbits, all animals died within 24 hours after dosing with 0.5 mL or less of terbufos (guidelines 81-4, 81-5; MRID 00044957, 00037467). No dermal sensitization study has been performed due to the acute lethality of terbufos. The compound was not neurotoxic when administered in a single oral dose of 40 mg/kg to hens in an acute delayed neurotoxicity study (guideline 81-7; MRID 00037472).

# b. Subchronic Toxicity

Dietary administration of terbufos for three months to Sprague Dawley rats at concentrations of 0, 0.00625, 0.0125, 0.025, or 0.05 mg/kg/day resulted in a systemic NOEL of 0.0125 mg/kg/day. The systemic LOEL was 0.025 mg/kg/day based on increased liver weight and liver extramedullary hematopoiesis. Mesenteric and mandibular lymph node hyperplasia were found at the highest dose. The NOEL for cholinesterase (ChE) inhibition was 0.0125 mg/kg/day. The NOEL was based on 17% inhibition of plasma cholinesterase at concentrations in excess of 0.0125 mg/kg/day (guideline 82-1; MRID 00109446).

A 30 day dermal toxicity study with New Zealand white rabbits used doses of 0, 0.004, 0.02, or 0.10 mg/kg applied to intact and abraded skin (MRID 00085169). This study was determined to fulfill the toxicology requirements for guideline 82-2. The only effect found was slight erythema, which generally abated by the

end of the study, found at 0.1 mg/kg/day, the LOEL. Cholinesterase activity was not measured. The systemic NOEL was 0.02 mg/kg (guideline 82-2; MRID 00085169).

A 21-day inhalation study was performed with Sprague-Dawley rats. The rats were exposed in inhalation chambers to vapors of technical terbufos for 3 weeks at target concentrations of 0, 0.005, 0.01, 0.05 or 0.10  $\mu$ g/L. The mean analytical concentrations were 0, 0.0117, 0.0243, 0.0458, or 0.0946  $\mu g/L$  for males and 0, 0.0112, 0.0256, 0.0468, or 0.1001  $\mu$ g/L for females. The highest dose tested (HDT) showed a statistically significant decrease in red blood cell (RBC), plasma and brain cholinesterase in male or female rats on day 21. The chamber concentrations were not well controlled and wide variations in daily concentrations were noted. Due to this fact the lowest mean chamber concentrations were selected for the NOEL and LOEL. cholinesterase NOEL is 0.01  $\mu g/L$  or 0.001 mg/kg/day (MRID 00258710). The cholinesterase LOEL is 0.04  $\mu g/L$  based on significant decreases in plasma, RBC and brain cholinesterase in the 0.1  $\mu$ g/L dose group. This study was not designed to satisfy the requirements of a subchronic toxicity test because of the short duration, the number of animals/group, no individual clinical data and the fact that no histopathology was performed. Therefore, this study presents supplementary data.

A 28-day oral toxicity study with dogs was performed to define the plasma cholinesterase effect levels that were not achieved in the one year oral beagle dog study (MRID 00161572). The study was performed at dose levels of 0, 0.00125, 0.005 or 0.015 mg/kg/day given orally by capsule. The plasma cholinesterase NOEL was 0.005 mg/kg/day (MRID 40374701). The plasma cholinesterase LOEL of 0.015 mg/kg/day was based on a 58-64% decrease in plasma cholinesterase in male and female dogs.

# c. Chronic toxicity

A one-year oral toxicity study was performed in Charles River CD rats with terbufos doses of 0, 0.125, 0.5, or 1.0 ppm in the diet (equivalent to 0, 0.007, 0.028, or 0.055 mg/kg/day for males and 0, 0.009, 0.036 or 0.071 mg/kg/day for females) (guideline 83-1; MRID 40098602). The systemic NOEL was greater than 1.0 ppm (0.055 mg/kg/day). The NOEL for cholinesterase inhibition was 0.5 ppm (0.028 mg/kg/day), based upon reductions in brain and

plasma cholinesterase levels in both sexes at the next highest dose of 1.0 ppm.

In a one-year oral beagle dog study, the doses of terbufos administered by capsule were 0, 0.015, 0.06, 0.09, or 0.12 mg/kg/day (quideline 83-1; MRID 00161572). The systemic NOEL was ≥ 0.12 mg/kg/day, the highest dose tested. Initial higher doses of 0.024 and 0.048 mg/kg/day were reduced after the first 6-8 weeks of the study due to cholinergic-related behavioral signs, reduced food consumption and weight gain, depressed hematology parameters, and gross changes of congestion, edema and necrosis in the gastro-intestinal tract. A NOEL for plasma cholinesterase inhibition was not determined because plasma cholinesterase inhibition was found in all treated dose levels. Red blood cell (RBC) cholinesterase activity in male dogs was moderately reduced ( $\approx$  20%) in the 0.09 and 0.12 mg/kg/day dose groups at week 13. This percent reduction in RBC activity was consistently observed at subsequent sampling periods. A similar pattern was observed in females with RBC cholinesterase activity being depressed slightly more during the 13 week period in the two highest dose groups. A NOEL for RBC cholinesterase inhibition was 0.06 mg/kg/day. Brain cholinesterase inhibition was more variable, but generally supported a depression of cholinesterase activity in the two high dose groups.

# d. Carcinogenicity

Terbufos was examined for potential carcinogenic activity in rats and mice. Long Evans rats were given 0, 0.0125, 0.05 or 0.1 mg/kg/day in the diet initially, the levels were then raised to 0.2 and 0.4 mg/kg/day after 6 and 12 weeks, respectively, with the females at 0.4 mg/kg/day reduced back to 0.2 mg/kg/day after 16 weeks (guidelines 83-1, 83-2; 00049236). No neoplastic activity was observed after two years of dosing. In this study, the LOEL was 0.05 mg/kg/day for systemic toxicity, based on mortality and exophthalmia. Significant cholinesterase inhibition, in red blood cells and brain, was found at 0.05 mg/kg/day and at higher doses; in addition, there was inhibition in red blood cells at 0.0125 mg/kg/day. The NOEL for ChE inhibition was less than 0.0125 mg/kg/day.

In another study, dietary doses of 0, 0.45, 0.9 or 1.8 mg/kg/day of terbufos were administered to CD-1 mice for 18 months. No

carcinogenic effects were observed (guideline 83-2; 40098603). The systemic NOEL in this study appeared to be 0.9 mg/kg/day, based upon a slight increase in mortality and reduction in weight gain at 1.8 mg/kg/day in both sexes of mice. Terbufos has been classified by the HED RfD Committee as a Group E chemical.

# e. Developmental Toxicity

Developmental toxicity studies with terbufos were conducted in rats and rabbits. Doses of 0, 0.05, 0.1 or 0.2 mg/kg/day were administered by gavage on gestation days 6-15 to COBS (CD) rats. The maternal toxicity NOEL in rats was greater than 0.2 mg/kg/day (highest dose tested) and the developmental toxicity NOEL was 0.1 mg/kg/day. The developmental toxicity LOEL of 0.2 mg/kg/day was based on increases in early fetal resorptions, the number of litters with 2 or more resorptions, and post-implantation losses (guideline 83-3; MRID 00147533).

In New Zealand white rabbits, doses of 0, 0.05, 0.10, 0.25, or 0.50 mg/kg/day were administered by gavage on gestation days 7-19. The maternal toxicity NOEL was 0.1 mg/kg/day and the LOEL was 0.25 mg/kg/day. Reduced weight gain and soft stools occurred at 0.25 mg/kg/day and at 0.5 mg/kg/day, the highest dose tested. The developmental toxicity NOEL was 0.25 mg/kg/day. The developmental toxicity LOEL was 0.5 mg/kg/day based on a slight reduction in fetal body weight and an increase in resorptions (guideline 83-3; MRID 40886301). No compound-related developmental effects were reported for external, visceral, or skeletal observations in either rats or rabbits with terbufos.

# f. Reproductive Toxicity

A three-generation reproduction study in Long-Evans rats used doses of 0, 0.0125, or 0.05 mg/kg/day (MRID 00085172). The NOEL was 0.05 mg/kg/day as no adverse effects were shown. The study does not meet the requirements for guideline 83-4. However, no other study of this type is required, on the basis that higher doses would be expected to produce cholinesterase inhibition, as was found in chronic studies at slightly higher doses.

# g. Mutagenicity

A dominant lethal study with terbufos was performed in rats to

test for structural chromosomal aberrations. A possible compound-related effect on fertility occurred in the high dose group (0.4 mg/kg), where the number of viable implants was reduced and implantation efficiency was lower (MRID 00161571). However, terbufos was not mutagenic in a variety of other studies when tested to cytotoxic levels. Those designed to detect gene mutations were the Ames reversion assay with S. typhimurium and E. coli strains (MRID 00063209) and the CHO/HGPRT assay in vitro Tests for structural chromosomal aberrations (MRID 00133297). included the Chinese hamster ovary cells in culture (MRID 00133296) and the in vitro cytogenetics assay in rats (MRID 00161570). Tests for other genotoxic effects were the rat hepatocyte primary culture/DNA repair test (MRID 00133298) and the effects on DNA repair in S. typhimurium and E. coli strains (MRID 00063209). (These studies fulfill the requirements of quideline 84.)

# h. Metabolism

A metabolism study in rats (MRID 00087695) indicated that a single administration of 0.8 mg/kg of terbufos C14 in the diet to male rats results in 83% of the administered dose being excreted in the urine in the form of metabolites and 3.5% in the feces over 168 hours. There was no unusual localization of terbufos or its metabolites in tissues. Several metabolites of terbufos have been identified, including phosphorus-containing metabolites (esters of phosphorothioic and phosphorodithioic acids) and nonphosphorus metabolites (Parkin, 1973). Additional rat metabolism studies consisting of single oral low and high doses, and 14-day repeated oral exposure with the low dose are required to fulfill Agency requirements (Levy, 1990).

# i. Toxicological Endpoints of Concern

The Reference Dosé (RfD) for chronic oral exposure was determined to be 0.00005 mg/kg/day based on a NOEL of 0.005 mg/kg/day for plasma cholinesterase inhibition in a 28-day study in dogs. The 28-day and the 1 year dog studies should be considered co-critical studies; since the 28-day dog study was performed because the 1 year dog failed to demonstrate a plasma cholinesterase NOEL. The toxicological endpoint of concern is cholinesterase activity with plasma being the most sensitive indicator. A safety factor of 100 was utilized (10 for intra-

and interspecies variation each). The Joint Meeting on Pesticide Residues (JMPR) acceptable daily intake (ADI) is 0.0002 mg/kg (Summary of Toxicological Evaluations, IPCS, 1993). The ADI is based on a NOAEL of 0.016 mg/kg/day from a 3-generation reproduction study in rats.

The HED Less-than-Lifetime Committee met in January 1995 and identified the NOEL based on cholinesterase inhibition from the 28-day toxicity study in dogs as the endpoint of concern for the acute dietary, short and intermediate-term occupational/residential dermal exposure scenarios (Ioannou, 1995). Short-term exposure is defined as a duration of 1 to 7 days for occupational/residential exposures. Intermediate exposure is defined as 1 week to several months for occupational/residential exposures. The Less-than-Lifetime Committee also identified the NOEL based on cholinesterase inhibition from the 21-day inhalation toxicity study in rats as the endpoint of concern for the short and intermediate-term occupational/residential inhalation exposure scenarios (Ioannou, 1995). In the absence of dermal absorption data, the Agency assumed 100% (default assumption).

# II. EXPOSURE ASSESSMENT

#### a. Use Pattern

Terbufos is an organophosphate insecticide/nematicide. is formulated as a granular product (15 and 20 percent active ingredient). Occupational exposure is expected, based upon the currently registered uses of this pesticide. Terbufos is applied at planting or postemergence to terrestrial food and feed crops. Crops treated are corn (field, pop, and sweet), grain sorghum, and sugar beets (including tops as a feed crop). All application methods require soil incorporation. Terbufos is applied to the soil as an in-furrow treatment (drill equipment, band treatment, or direct-incorporation treatment). The registrant is not supporting a previously registered aerial/broadcast treatment. Applications are made as often as twice per season. Based on the currently registered use-sites, terbufos is not used in a greenhouse. The maximum application rates are: for corn 1.97 lb ai/acre, for grain sorghum 3.92 lb ai/acre, and for sugar beets 4.35 lb ai/acre.

The mixer/loader/applicator exposure estimates are derived from the Pesticide Handlers Exposure Database (PHED V1.1). This data was used to calculate daily dermal and inhalation exposure for workers handling terbufos in treating the registered sites. The PHED data are based on two major exposure scenarios 1) loading the dry (granular) formulation and 2) applying the dry formulation with granular-spreader equipment.

# b. Dietary Exposure

Residue chemistry data requirements are satisfied, with the exception of Guideline §165-2; additional confirmatory limited field trials are required to determine if rotational crop tolerances are necessary. Conclusions are summarized below.

§171-4 (a): Plant Metabolism: The 1983 Residue Chemistry Chapter, as well as the 1987 FRSTR and 1988 Guidance Document concluded that the qualitative nature of the residue in plants is adequately understood. Studies conducted on corn, sugar beets, soybeans, sorghum, cabbage, rape, and wheat indicate that the residues of concern in plants are terbufos and its phosphorylated (cholinesterase-inhibiting) metabolites (terbufoxon sulfoxide, and terbufoxon sulfone).

§171-4 (b): Animal Metabolism: The qualitative nature of the residue in poultry is adequately understood. Radioactive residues in poultry tissues and eggs were non-detectable following dosing of laying hens at up to 30X the maximum anticipated dietary burden. It was concluded that residues resulting from an anticipated 1X exposure would not exceed 0.01 ppm in poultry tissues and eggs.

The qualitative nature of the residue in ruminants is adequately understood. The residues of concern in ruminants are terbufos and its phosphorylated (cholinesterase-inhibiting) metabolites. Treatment of goats at exaggerated terbufos dose levels resulted in regulated terbufos residue levels of <0.01 ppm in milk, liver and kidney (MRID Nos. 43237801 and 43237802. CBRS Nos. 13803 and 13804).

§171-4 (c) and (d): Residue Analytical Methods-Plants and Animals: An adequate method is available for data collection and enforcement of terbufos tolerances in or on plant commodities.

The GLC/flame ionization-detection method for determining terbufos and its phosphorylated metabolites is described in PAM, Vol. II, as Method I. The hazardous reagent benzene is specified in this method.

Method M-1754, a modification of Method I in PAM that substitutes acetone for benzene and methylene chloride for chloroform, underwent a successful Residue Analytical Laboratory method validation trial and was forwarded to FDA for revision of PAM, Vol II.

<u>\$171-4 (e):</u> Storage Stability: No additional storage stability data are required. The available storage stability data indicate that residues of terbufos, terbufoxon sulfoxide, and terbufoxon sulfone are stable in or on corn grain, forage, and fodder, sorghum grain, forage and fodder, and in or on sugar beet roots and tops stored at -10 °C for up to 2 years.

# §171-4 (k): Magnitude of the Residue in Plants and Animals:

No additional residue data are required to support existing tolerances for terbufos residues in/on plant commodities; however, amended labels specifying a 150-day PHI for sugar beets and a 60-day PHI for sweet corn (K + CWHR) are required. Labels must be amended to specify a 50-day pre-grazing/feeding interval for sorghum forage, and a 100-day PHI for sorghum grain and fodder.

# §171-4 (1): Magnitude of the Residue in Processed Commodities:

The requirements for corn and sorghum processing studies were waived by the Agency [CBRS No. 13593, C. Swartz, 5/5/94]. (The tolerance in the RAC should be used in assessing the dietary risk associated with corn processed fractions.)

# §171-4 (j): Magnitude of the Residue in Meat, Milk, Poultry, and Eggs:

Based on poultry metabolism data in which a 30X dose resulted in nondetectable (<0.01 ppm) residues in laying hen tissues and eggs, it was concluded that residues resulting from 1X the dietary burden would not be detectable in poultry tissues and

eggs. This is equivalent to classification of terbufos residues in poultry under 40 CFR §180.6(a)(3), and therefore no tolerances for terbufos residues in poultry commodities are required.

Based on a goat metabolism study (MRID 42576901) in which a 10X dose resulted in non-detectable (<0.01 ppm) regulated terbufos residues in meat, milk, liver and kidney, it was concluded that terbufos residues in meat and milk can be classified under 40 CFR §180.6(a)(3), i.e. there is no reasonable expectation of finite residues. No tolerances are required. Reserved ruminant feeding studies are not required.

# §165-1 Confined Rotational Crops:

A confined rotational crop study was submitted and determined to be adequate to fulfill the data requirements for this guideline. A field rotational crop study was required, based on the results of the confined study.

# §165-2 Field Rotational Crops:

The required field rotational crop studies were submitted. Rotated spring wheat, sugar beets, and cabbage were planted about 30 days after the corn field had been treated. Terbufos residues were less than 0.05 ppm in the tops and roots of beets, in whole cabbages, and in wheat grain; wheat straw contained residues of 0.10 ppm; spring wheat forage had residues of 0.15 ppm. Additional confirmatory limited field trials are required to determine if rotational crop tolerances are necessary because the limited field trials involved analysis of single samples for each crop matrix, and residues were found in wheat forage and straw.

# c. Occupational-use products and homeowner-use products

At this time no products containing terbufos are intended primarily for homeowner use. All products containing terbufos are intended primarily for occupational use. None of the registered occupational uses are likely to involve applications at residential sites.

# d. Handler Exposures & Assumptions

EPA has determined there is a potential exposure to mixers, loaders, applicators, or other handlers during usual use-patterns associated with terbufos. Of particular concern are dermal and inhalation exposures during loading of terbufos granular into hoppers and dermal and inhalation exposures during application. Mixer/loader/applicator (M/L/A) exposure data for terbufos were required during Phase IV of the reregistration process, since one or more toxicological criteria had been triggered at that time.

Exposure was estimated for handlers treating corn using typicaland maximum-size treated areas and typical and maximum application rates, since these data were available from the Corn Cluster Assessment (BEAD-supplied data). Typical application rates were not available for sugar beets or grain sorghum. Exposure was estimated for handlers treating these crops using typical- and maximum-size treated areas and maximum application rates (LUIS-supplied data).

Table 2 describes the simulated clothing/equipment used to calculate the exposure values reported in Tables 3 and 4. The dermal exposure scenarios are presented in Table 3 and the corresponding inhalation exposure assessment in Table 4. The footnotes summarize the caveats and parameters specific to each exposure scenario. Protection factors were applied, in some instances, to the dermal exposure data reported in Table 3 to simulate use of the following personal protective equipment:

# • For loaders

PPE represents loaders using open loading systems while wearing chemical-resistant gloves plus coveralls worn over long pants and long sleeve shirt;

Engineering controls represent loaders using closed loading systems (lock 'n load) while wearing long pants and long-sleeve shirts. (Since actual exposure data were not available, a 90 percent protection factor was used to simulate Lock'N Load closed granular loading.)

# For applicators

PPE represents applicators using open cab tractors while

wearing chemical-resistant gloves plus coveralls over long pants and long-sleeve shirts. (A 98 percent protection factor was used to back-calculate from enclosed-cab data to simulate an open-cab-tractor scenario.)

Engineering controls represent applicators using enclosed cabs while wearing long-sleeve shirts and long pants. (A 90 percent protection factor was used to back-calculate to simulate workers wearing no gloves while in an enclosed cab.)

Protection factors were applied to the inhalation exposure data reported in Table 4 to simulate use of the following personal protective equipment:

#### • For loaders

PPE represents loaders using open loading systems while wearing a respirator with an organic-vapor-removing cartridge and a prefilter approved for pesticides. (A 90 percent protection factor was used to simulate wearing the respirator.)

Engineering controls represent loaders using closed loading systems (lock 'n load) while wearing chemical-resistant gloves. (A 90 percent protection factor was used to simulate Lock & Load closed granular loading.)

# • For applicators:

PPE represents applicators using open cab tractors while wearing a respirator with an organic-vapor-removing cartridge and a prefilter approved for pesticides. (A 90 percent protection factor was used to simulate wearing the respirator.)

Engineering controls represent applicators using enclosed cabs. (A 90 percent protection factor was used to simulate an enclosed-cab system with an air-filtration system equivalent to the organic-vapor cartridge respirator with a pesticide prefilter.)

CRIPTION	Comments	•		PPE: Dermal and inhalation acceptable grades.  Dermal = 12 to 45 replicates: Inhalation = 58 replicates.  Medium confidence in the dermal data. High confidence in the inhalation data.  Engineering Controls: Dermal all grades, inhalation acceptable grades.  Dermal = 10 to 78 replicates; Inhalation = 58 replicates.  Low confidence in the dermal data. High confidence in the inhalation data.		PPE: Dermal and inhalation acceptable grades.  Dermal = 2 to 17 replicates; Inhalation = 17 replicates.  Low confidence in the dermal data. High confidence in the inhalation data.  Engineering Controls: Dermal and inhalation acceptable grades; Dermal = 2 to 17 replicates; Inhalation = 17 replicates.  Low confidence in the dermal data. High confidence in the inhalation data.
ARIO DES	Standard Assumptions <sup>b</sup>	(8-hr work day)		Loading for typical and maximum acreage and rates for sugar beets, grain sorghum, and com		Application of typical and maximum acreage and rates for sugar beets, grain sorghum, and com:
SURE SCEN	ment	Engineering Controls	*	Closed loading granulars using a Lock & Load system		Enclosed cab tractor
CATOR EXPC	Equipment	Hope .	Mixer/Loader Exposure	Open loading granulars	A and inclined Evenorisms	Open cab tractor
MIXER/LOADER/APPLICATOR EXPOSURE SCENARIO DESCRIPTION	cenario	Engineering Controls	Mis	Long sleeved shirt and long pants; no gloves; no respirator		Long sleeved shirt and long pants; no gloves; no respirator
TABLE 2: MIXER/	t 13	PPE		Coveralls over long sleeved shirt and long pants; chemical resistant gloves; respirator with organic vapor removing cartridge.		Coveralls over long sleeved shirt and long pants; chemical resistant gloves; respirator with organic vapor removing cartridge.
TABI	Data	Source		PHED V1.1		PHED VI.1
-	Exposure Scenario	(Number)		Loading Granulars (1)		Granular Row Planter (II)

Clothing represents the exposure estimates used in Table 2. Standard Assumptions based on an 8-hour work day as described in Table 2. "Acceptable grades." as defined by OREB SOP for meeting Subdivision U Guidelines, are grades A and B for dermal, hand, and inhalation matrices. All grades that do not meet OREB's SOP are "Acceptable grades." as defined by OREB SOP for meeting Subdivision U Guidelines, are grades A and B for dermal, hand, and inhalation matrices. All grades that do not meet OREB's SOP are Issued individually.

- 1995 REVISED ASSESSMENT -

Exposure Scenario (Number)	Der	Dermal Exposure Crop Label Application Daily Acres (mg/lb ai) Treated	Crop	Label Application Rates (lb ai/acre)	Daily Acres Treated	Daily Der	Daily Dermal Dose' (mg/kg/day)
	PPE	Engineering Controls				PPE	Engineering Controls
			Mixer/Loader Exposure	osare			
	-		/	Typical Ácre	Typical Acres Treated at Maximum Rates	imum Rates	
Granular Loaders (1)	0.003	0.001	Sugar Beets	4.35		6.013	0.0043
			Grain Sorghum	3.92	69	0.012	0.0039
			Com	1.97	3	0.0058	0.0019
		÷		Maximum Ac	Maximum Acres Treated at Maximum Rates	ximum Rates	
	•		Sugar Beets	4.35		0.040	0.013
			Grain Sorghum	3.92	213	9:00	0.012
		· · ·	Сош	1.97		0.018	0.0060
			`	Typical Ac	Typical Acres Treated at Typical Rate	pical Rate	
•			Com	1.12	69	0.0033	0.0011
				•	001	0.0048	0.0016
-			3	Maximum	Maximum Acres Treated at Typical Rate	ypical Rate	
-			Corn	1.12	213	0.010	0.0034
			Applicator Exposure	sure	,		
					Typical Acres Treated at Maximum Rates	imum Rates	
Granular Row Planters (11)	0.2	0.003	Sugar Beets	4.35		98.0	0.013
			Grain Sorghum	3.92	,	0.78	0.012
			Com	1.97	}	0.39	0.0058
				Maximum Ac	Maximum Acres Treated at Maximum Rates	ximum Rates	
· .			Sugar Beets	4.35		2.6	0.040
	-		Grain Sorghum	3.92	213	2.4	0.036
			Com	1.97		1.2	0.018
				Typical A	Typical Acres Treated at Typical Rate	pical Rate	
,			Сот	1.12	69	0.22	0.0033
		. /		•	001	0.32	0.0048
				Maximum A	Maximum Acres Treated at Typical Rates	ypical Rates	
			Chan	1 12.	213	0.68	0.010

- <sup>4</sup> The PPE represents coveralls over long pants, long sleeved shirt, chemical resistant gloves while using open systems. The engineering controls represent long pants, long-sleeved shirt, no gloves and closed systems (i.e., Lock & Load or enclosed cabs).
- <sup>b</sup> Maximum application rate based on labelled uses and LUIS report for terbufos.
- e Acres treated are based on 8 row planters (69 acres/day) and 20 row planters (213 acres/day) and a typical application rate of 1.12 lb ai/A for corn.
- Daily Dermal Dose (mg/kg/day) = Exposure (mg/lb ai) \* Max. Appl. Rate (lb ai/acre) \* Max. Treated

raily Definal Dose (ingresous) - <u>Capasine (ingresous)</u> 70 kg

where:

application rates and acres treated can be typical or maximum as discussed in the text. Typical application rate is only available for corn.

33

- 1995 REVISED ASSESSMENT -

TABIE 4:	NHALATI	ON EXPOSU	INHALATION EXPOSURE MIXER/LOADER/APPLICATOR	DER/APPLICA	FOR	TERBUFOS
umber)	Inhalation (mg	Inhalation Exposure (mg/lb ai)		Label Application Rates	Daily Acres	Daile Inhalation Dass
	PPE	Engineering Controls	Crop	(16 al/acre)	Lealed	(mg/kg/day)
			Mixer/Loader Exposure			
		7		Typical Acres Treated at Maximum Rates	ted at Maximum R	ates
Granular Loaders (1)	2 x 10 <sup>-1</sup>	2 x 10 <sup>-4</sup>	Sugar Beets	4.35		8.6 x 10 <sup>4</sup>
			Grain Sorghum	3.92	69	7.8 x 10 <sup>-4</sup>
· ·			Com	1.97	`	3.9 x 10 <sup>-4</sup>
				Maximum Acres Treated at Maximum Rates	ated at Maximum	Rates
		,	Sugar Beets	4.35		2.6 x 10 <sup>1</sup>
			Grain Sorghum	3.92	515	2.4 x 10°
			Com	16.1		1.2 x 10 <sup>-1</sup>
				Typical Acres Tr	Typical Acres Treated at Typical Rate	ite
1	-		Com	1.12	69	2.2 x 10 <sup>-4</sup>
•					001	3.2 x 10 <sup>-4</sup>
-		٠,		Maximum Acres 1	Maximum Acres Treated at Typical Rate	(વાલ
			Com	1.12	213	6.8 x 10⁴
			Applicator Exposure			
	•			Typical Acres Treated at Maximum Rates	ted at Maximum R	ates
One Desired (11)	101.44	4 x 10 <sup>-1</sup>	Sugar Beets	4.35		1.7 x 10°
Olaimiai Now Frances (11)	:		Grain Sorghum	3.92		1.6 x 10 <sup>-3</sup>
	•		Com	1.97	69	7.8 x 10 <sup>-1</sup>
				Maximum Acres Treated at Maximum Rates	eated at Maximum	Rates
	4.		Sugar Beets	4.35	-	5.3 x 10 <sup>1</sup>
			Grain Sorghum	3.92		4.8 x 10 <sup>-3</sup>
			Com	1.97	213	2.4 x 10 <sup>-1</sup>
				Typical Acres Tr	Typical Acres Treated at Typical Rate	ગાલ
-			Соги	1.12	69	4.4 x 10 <sup>-4</sup>
					100	6.4 x 10 <sup>-4</sup>
		,		Maximum Acres Treated at Typical Rates	reated at Typical R	
			Corn	1.12	213	1.4 x 10°

# 1995 REVISED ASSESSMENT

- respirators, but loading and applying the pesticide within closed systems (i.e., Lock & Load or enclosed cab). Since the protection afforded by the respirator is equivalent to the Lock & <sup>a</sup> The PPE inhalation exposure values are for workers wearing organic vapor removing respirators (90 fold PF used). The engineering control values are for workers wearing no Load or an enclosed cab with proper positive pressure filtration (i.e., inhalation exposure values are the same), only one set of daily dose and MOE are calculated.
- Maximum application rate based on labelled uses and LUIS report for terbufos.
- e Acres treated are based on 8 row planters (69 acres/day) and 20 row planters (213 acres/day) and a typical application rate of 1.12 lb ai/A for corn.
- Daily Inhalation Dose (mg/kg/day) = Exposure (mg/lb ai) \* Max. Appl. Rate (lb ai/acre) \* Max. Treated

where:

application rates and acres treated can be typical or maximum as discussed in the text. Typical application rate is only available for corn.

NOEL = 0.01 mg/m<sup>3</sup> 
$$\left( \frac{0.01 \text{ mg/m}^3 \times 10 \text{ m}^3/\text{day}}{70 \text{ kg}} = 0.0014 \text{ mg/kg/day} \right)$$

here:

10 m³ is the volume of air inhaled in a typical eight hour work day (OSHA Docket H-049, 1993)

# Post-Application Exposures & Assumptions

EPA has determined the potential exposure to persons entering treated sites after application is minimal as long as: (1) the application is incorporated correctly, or (2) the reentry task does not involve contact with the soil subsurface.

THIS SECTION IS INCOMPLETE. IT CANNOT BE COMPLETED UNTIL HANDLER RISK-MITIGATION MEASURES ARE FINALIZED.

# Post Application/Reentry/Exposure

Foliar residue dissipation data (132-1a) were required for aerial/broadcast applications in arid climates (i.e., rainfall less than 25 inches), according to the terbufos Registration Standard (September, 1988). A post-application reentry interval of 7 days was specified for broadcast applications without soil incorporation. The registrant is not supporting broadcast applications. Therefore, potential post-application/reentry exposures to terbufos applications are limited to granular terbufos soil incorporation treatments for which the 7 day REI will not be required.

No reentry data are required, since post-application foliar and soil exposures are likely to be minimal. For chemicals in this toxicity category (acute dermal I), the Worker Protection Standard PR Notice 93-7 Supplement Three-A requires an REI of 48 hours and an REI of 72 hours in arid (less than 25 inches of precipitation) climates. REIs provided in the Worker Protection Standards are expected to be adequate, because the aerial/broadcast applications are not supported by the registrant.

# e. Incidence Data

Of the 28 organophosphates and carbamates examined in the Agency's Acute Worker Risk Strategy (AWRS), terbufos had one of the highest estimated dermal toxicities for a formulated product (8-10 mg/kg body weight for 15-20% granular formulations). Two deaths from ingestion of terbufos were reported in 1990 (EPA Region 5 report and American Association of Poison Control Centers Annual Report), but no deaths were reported from dermal exposure to terbufos. No deaths or poisonings have been reported in California since 1980, however no usage was reported for California either.

The American Association of Poison Control Centers maintains a Toxic Exposure Surveillance System which is one of the only available sources of data on terbufos poisoning. A total of 80 occupational exposures, 49 non-occupational exposures to adults, and 19 exposures in children under six years of age were reported to the Poison Control Center between 1985 and 1992. chemicals in the AWRS were ranked on the basis of percent with symptoms, life threatening effects, requirement for medical care, or hospitalization. Terbufos ranked fifth overall for occupational cases and third overall for non-occupational adults. However, when the frequency of symptoms, life-threatening symptoms, health care and hospitalization were adjusted for national estimates of use (pounds active ingredient), terbufos exhibited lower ratios than the median for other organophosphates and carbamates used in agriculture. This suggests that the incidence of terbufos poisonings in workers at risk may be low, though when over-exposed poisoning may be more likely to be serious.

### III. RISK CHARACTERIZATION

## a. Dietary Risk

# i. Acute Risk Analysis

As previously stated the acute dietary endpoint (one day) is based on the NOEL for plasma cholinesterase inhibition (0.005 mg/kg/day) in dogs (MRID 40374701).

Acute dietary exposure analysis estimates the distribution of single-day exposures for the U.S. population and certain subgroups. The analysis evaluates individual food consumption as reported by respondents in the 1977-78 Nationwide Food Consumption Survey and accumulates exposure to terbufos for each food commodity which has a terbufos tolerance. As such, the exposure estimate is a maximal estimate because it assumes that terbufos residues are present at the maximum legal limit in the entirety of the commodities in which they can occur.

The RACs (Raw Agricultural Commodities) and tolerances, used in this assessment, were derived from 40 CFR 180.352 and the Tolerance Index System and are listed below and in Appendix A:

RAC	Tolerance (ppm)
Bananas	0.025
Coffee	0.05

Beets, Sugar (Roots)	0.05
Corn, Grain	0.05
Corn, Sweet	0.05
Sorghum, Grain	0.05

The Margin of Exposure (MOE) for acute dietary risk was calculated for the U.S. population and for four population subgroups. The calculated MOEs using a NOEL of 0.005 mg/kg bodyweight/day were:

Population Groups	Percentile Pop.	MOE
U.S. population Infants (Less Than One Year Old) Children (1-6 Years Old) Females (> or = 13 Years Old) Males (> or = 13 Years Old)	96th 96th 98th 93rd 91st	25 10 10 50 50
Margin of = NOEL Exposure exposure		

An acute Margin of Exposure (MOE) using a NOEL based on animal data that is  $\geq$  100 for the U.S. Population, or any of its subgroups that are analyzed by the DRES system, is generally considered not to be of concern. In the current analysis terbufos appears to present acute dietary risk concerns for all populations evaluated.

# ii. Chronic Risk Analysis

As previously stated the Reference Dose (RfD) for chronic oral exposure was determined to be 0.00005 mg/kg/day based on a NOEL of 0.005 mg/kg/day for plasma cholinesterase inhibition in a 28 day oral study in dogs.

The total TMRC (Theoretical Maximum Residue Contributions) exposure for dietary exposure from terbufos for the U.S. population was estimated as being 0.000052 mg/kg bodyweight per day and the risk estimate was 104% of the Reference Dose (RfD). The subgroups with the highest estimated dietary TMRC exposures/risks were:

Subgroup	TMRC Exposure	TMRC Risk
U.S. Population	0.000055	110% RfD
Non-nursing Infants	•	
(< 1 Year Old)	0.000116	232% RfD
Children (1 to 6 Years Old)	0.000131	262% RfD
Children (7 to 12 Years Old)	0.000089	178% RfD
<pre>*mg/kg bodyweight per day</pre>		

Adjustments of the TMRC exposure, by inclusion of percent crop treated data for Field Corn; Sweet Corn; Sorghum; and Sugar Beets, Roots in the DRES terbufos file to produce ARCs (Anticipated Residue Contributions) for the same subgroups, substantially lowered the estimates of chronic dietary exposure and risk to terbufos. The total dietary ARC exposure of the U.S. population was estimated as being 0.000016 mg/kg bodyweight per day and the risk estimate was 33% of the RfD. The subgroups with the highest estimated dietary total ARC exposures/risks were:

Subgroup	ARC Exposure*	ARC Risk
Non-nursing Infants (<1 Year Old)	0.000040	81% RfD
Children (1 to 6 Years Old)	0.000039	77% RfD
Children (7 to 12 Years Old)	0.000022	44% RfD
<pre>*mg/kg bodyweight per day</pre>	8 a	

A recently published FR notice for a tolerance in coffee was included in the above assessment. The raw agricultural commodities which contribute the most ARC exposure/risk for U.S. populations from dietary terbufos are; bananas, corn (all), and beets (sugar). Pending tolerances, especially for the RAC soybeans, increase the ARCs of the infant and children subgroups greater than the RfD.

For each of the subgroups with a total terbufos dietary ARC exposure (risk) estimate that exceeds the RfD, the total estimated ARC contributions of the commodities that currently have Pending tolerances, versus those that have Published tolerances, are as follows:

# DIETARY RISK COMPARISON FOR PENDING AND PUBLISHED TOLERANCES

POPULATION GROUP	PENDING TO	LERANCES	PUBLISHED TO	LERANCES
	EXPOSURE1	RISK <sup>2</sup>	EXPOSURE1	RISK <sup>2</sup>
Non-Nursing Infants (> yr)	0.000083	166	0.000040	81
Children (1-6 yr)	0.000045	90	0.000039	77

Children	0.000034	68	0.000022	44
(7-12 yr)				

Exposure as mg/kg bodyweight per day.

Therefore, the Agency does not have concerns for chronic dietary exposure and resulting risk for uses being considered under reregistration.

# b. Occupational Risk

EPA has determined there is potential exposure to mixers, loaders, applicators, or other handlers during usual use-patterns associated with terbufos. Of particular concern are dermal and inhalation exposures during loading the dry (granular) formulation and applying the dry formulation with granular-spreader equipment.

Table 2 describes the simulated clothing/equipment used to estimate risks. Margins of exposure (MOEs) for occupational exposure were calculated for handlers using a NOEL of 0.005. mg/kg/day for short and intermediate-term dermal exposure and a NOEL of 0.01  $\mu$ g/L (0.0014 mg/kg/day) for short and intermediate-term inhalation exposure. The calculated dermal and inhalation MOEs are presented in Tables 5 and 6.

The estimated MOEs are all less than 100; with most being less than 5 for loaders and applicators of terbufos for all crop scenarios using both typical and maximum application rates and typical and maximum treated-area size. The MOEs for loaders and applicators are less than 100 even when engineering controls (closed loading system and enclosed cab with respiratory filtration system) are simulated. It should also be noted that if 50% dermal absorption was assumed the MOEs would still result in MOEs of less than 100.

# Risk From Post-Application Exposures

[Note: the following sections need to be addressed with the registrant, because all scenarios yield MOEs less than 100.]

THIS RISK ASSESSMENT HAS BEEN POSTPONED PENDING THE OUTCOME OF THE HANDLER RISK-MITIGATION DECISION.

<sup>&</sup>lt;sup>2</sup> Risk as percent RfD.

# Additional Occupational/Residential Exposure Studies

# Handler Studies

THIS DETERMINATION HAS BEEN POSTPONED PENDING THE OUTCOME OF THE HANDLER RISK-MITIGATION DECISION.

# Post-Application Studies

THIS DETERMINATION HAS BEEN POSTPONED PENDING THE OUTCOME OF THE HANDLER RISK-MITIGATION DECISION.

- 1995 REVISED ASSESSMENT -

TABLE 5:

AL EXPOSURE to TERBUFOS	MOE (dermal) <sup>d</sup>	PPE Engineering Controls			0.38 1.2	0.42 1.3	0.86 2.6	SS	0.13 0.38	0.14 0.42	0.28 0.83		1.5 4.5	1.0 3.1		0.50 1.5			0.0058 0.38	0.0064 0.42	0.013 0.86	Sc	0.0019 . 0.13	0.0021 0.14	0.0042 0.28		0.023 1.5	0.016 1.0		0.0074 0.50
FROM DERMAL	Daily Dermal Dose <sup>b</sup> (mg/kg/day)	Engineering Controls <sup>e</sup>		Typical Acres Treated at Maximum Rates	0.0043	0.0039	0.0019	Maximum Acres Treated at Maximum Rates	0.013	0.012	0900:0	Typical Acres Treated at Typical Rate	0.0011	9100.0	Maximum Acres Treated at Typical Rate	0.0034	,	Typical Acres Treated at Maximum Rates	0.013	0.012	0.0058	Maximum Acres Treated at Maximum Rates	0.040	0.036	0.018	Typical Acres Treated at Typical Rate	0.0033	0.0048	Maximum Acres Treated at Typical Rates	0100
SULTING	Daily Der (mg/l	PPE°	xposure	Acres Treated	0.013	0.012	0.0058	n Acres Treate	0.040	0.036	0.018	al Acres Treat	0.0033	0.0048	um Acres Trea	0.010	posure	Acres Treated	0.86	0.78	0.39	m Acres Treate	2.6	2.4	1.2	al Acres Treat	0.22	0.32	um Acres Trea	940
OF EXPOSURE RESULTING	Daily Acres Treated		Mixer/Loader Exposure	Typical			6	Maximur			213	Typic	69	001	Maxim	213	Applicator Exposure	Typical	8		60	Maximu		,	213	Typic	69	100	Maxim	213
	Crop				Sugar Beets	Grain Sorghum	Corn		Sugar Beets	Grain Sorghum	Corn		Corn			Com			Sugar Beets	Grain Sorghum	Corn		Sugar Beets	Grain Sorghum	Corn		Com			
OCCUPATIONAL MARGINS	Exposure Scenario (Number)				Granitar Loaders (1)							-							Granular Row Planters (II)			· ·						•		

- <sup>4</sup> Acres treated are based on 8 row planters (69 acres/day) and 20 row planters (213 acres/day) and a typical application rate of 1.12 lb ai/A for corn.
- b Daily Dermal Dose (mg/kg/day) = Exposure (mg/lb ai) \* Max. Appl. Rate (lb ai/acre) \* Max. Treated

where:

application rates and acres treated can be typical or maximum as discussed in the text. Typical application rate is only available for corn.

- The PPE represents coveralls over long pants, long sleeved shirt, chemical resistant gloves while using open systems. The engineering controls represent long pants, long-sleeved shirt, no gloves and closed systems (i.e., Lock & Load or enclosed cabs).
  - <sup>d</sup> MOE = NOEL / Daily Dermal Dose (mg/kg/day). NOEL = 0.005 mg/kg/day for oral study, dermal absorption data are not available, 100 percent is assumed.

- 1995 REVISED ASSESSMENT -

Table 6:

OCCUPATIONAL MARGI	NS	RE RESULT	OF EXPOSURE RESULTING FROM INHALATION	TON EXPOSURE to	o TERBUFOS
Exposure Scenario (Number)		Daily Acres Treated	Daily Inhalation Dose <sup>b.c</sup> (mg/kg/day)	MOE (inhalation) <sup>e.d</sup>	
	Mi	Mixer/Loader Exposure	sure		
		Typical Ac	Typical Acres Treated at Maximum Rates		
Granular Loaders (I)	Sugar Beets		8.6 x 10 <sup>-4</sup>	1.6	
	Grain Sórghum	07	7.8 x 10⁴	8.1	
٠	Corn	60	3.9 x 10⁴	3.6	
		Maximum A	Maximum Acres Treated at Maximum Rates		
	Sugar Beets		2.6 x 10 <sup>-3</sup>	0.54	
	Grain Sorghum	,,,	2.4 x 10 <sup>-3</sup>	0.58	
	Corn	\$11 <b>7</b>	1.2 x 10 <sup>-3</sup>	1.2	
	-	Typical /	Typical Acres Treated at Typical Rate		
	Corn	69	2.2 x 10⁴	6.4	
		001	3.2 × 10 <sup>-4</sup>	4.4	
		Maximum	Maximum Acres Treated at Typical Rate		
-	Com	213	6.8 x 10 <sup>-4</sup>	2.1	
		Applicator Exposure	ure		
		Typical Ac	Typical Acres Treated at Maximum Rates		·
Granular Row Planters (11)	Sugar Beets		1.7 x 10 <sup>-3</sup>	0.82	
	Grain Sorghum		1.6 x 10 <sup>-3</sup>	0.88	
	Com	69	7.8 x 10 <sup>-4</sup>	8.1	,
		Maximum A	Maximum Acres Treated at Maximum Rates		
	Sugar Beets		5.3 x 10 <sup>-3</sup>	0.26	
	Grain Sorghum		4.8 x 10 <sup>-3</sup>	0.29	
	Corn	213	2.4 x 10 <sup>-3</sup>	0.58	
		Typical /	Typical Acres Treated at Typical Rate		
	Com	, 69	4.4 x 10 <sup>-4</sup>	3.2	
		100	6.4 x 10 <sup>-4</sup>	2.2	:
		Maximum	Maximum Acres Treated at Typical Rates		
	Corn	213	1.4 x 10 <sup>-3</sup>	1.0	

# 1995 REVISED ASSESSMENT

<sup>a</sup> Acres treated are based on 8 row planters (69 acres/day) and 20 row planters (213 acres/day) and a typical application rate of 1.12 lb ai/A for corn.

b Daily Inhalation Dose (mg/kg/day) = Exposure (mg/lb ai) \* Max. Appl. Rate (lb ai/acre) \* Max. Treated

where:

application rates and acres treated can be typical or maximum as discussed in the text. Typical application rate is only available for corn.

loading and applying the pesticide within closed systems (i.e., Lock & Load or enclosed cab). Since the protection afforded by the respirator is equivalent to the Lock & Load or an enclosed cab with proper positive pressure filtration (i.e., inhalation exposure values are the same), only one set of daily dose and MOE are calculated. The PPE inhalation exposure values are for workers wearing organic vapor removing respirators (90 fold PF used). The engineering control values are for workers wearing no respirators, but

d MOE = NOEL / Daily Inhalation Dose (mg/kg/day).

NOEL = 0.01 mg/m<sup>3</sup> 
$$\left( \frac{0.01 \text{ mg/m}^3 \times 10 \text{ m}^3/\text{day}}{70 \text{ kg}} = 0.0014 \text{ mg/kg/day} \right)$$

where:

10 m³ is the volume of air inhaled in a typical eight hour work day (OSHA Docket H-049, 1993)

# Post-Application Risk

There is minimal potential for post-application exposure risk from the registered granular terbufos products under the requirements of the WPS when the product is applied according to label specifications. The post-application risk would be expected to be less than those risks associated with handler exposure. HED recommends retention of existing REIs (re-entry intervals), at 48 hours and 72 hours (arid regions) as currently required by the Worker Protection Standard PR Notice 93-7 for soil incorporated treatment by Terbufos. Personal protective equipment (PPE) selection for mixer/loaders/ applicators and other handlers is to be based on exposure to the end use product. Label statements to be included on all Terbufos labels are located on the Pesticide Worksheets--Parts One and Two: User Safety Statements, Application Restrictions, Entry Restrictions, Early Entry PPE, and Notification (Attached).

# Data Requirements

Confirmatory data are required as follows:

- 1) Acute inhalation toxicity data (Guideline 81-3) are required.
- 2) Additional field rotational crop (Guideline 165-2) data are required to fulfill residue chemistry data requirements.
- 3) Label amendments are required (Guideline 171-4(e)) for the RAC(s) sugarbeets, sweet corn(K+CWHR) as well as for sorghum grain, fodder and forage.

#### REFERENCES

- O0035121 Parke, G. S. E.; Terrell, Y. (1976). Acute Toxicity Studies in Rats. Compound: Enlist Technical Insecticide (terbufos). Report No. 6E-3164. Unpublished Aceto Chemical Co., Inc. study prepared by Cannon Laboratories.
- O0037467 American Cyanamid Company (1972). Toxicity Data: O,O-Diethyl-S-(tert-butylthiomethyl) phosphorodithioate
  Technical, 85.8%. Report No. A-72-95. Unpublished study prepared by American Cyanamid Co.
- 00037471 Kretchmar, B. (1972). Report to American Cyanamid:
  Acute Oral Toxicity Studies with Two Samples in Female
  Albino Rats. Report No. A 1373. Unpublished American
  Cyanamid Co. study prepared by Industrial Bio-Test
  Laboratories.
- O0037472 Smith, J. H., Rosselet, C.; Cannelongo, B. (1972). A
  Neurotoxicity Study of AC 92,100, an Organic Phosphate
  Cholinesterase Inhibitor, in Hens. Report No. 72S-788.
  Unpublished American Cyanamid Co. study prepared by
  Bio/Dynamics, Inc.
- 00044957 American Cyanamid Company (1972). Toxicity Data of 0,0-Diethyl- S-(tert-butylthiomethyl) phosphorodithioate. Report No. A-72-3. Unpublished study prepared by American Cyanamid Co.
- 00049236 Rapp, W. R.; Wilson, N. H.; Mannion, M. (1974). A
  Three and Twenty-Four Month Oral Toxicity and
  Carcinogenicity Study of AC 92-100 in Rats. Report No.
  71R-725. Unpublished American Cyanamid Co. study
  prepared by Bio/Dynamics, Inc.
- O0063209 Allen, J. S.; Johnson, E.; Wainwright, C (1977).

  Mutagenicity Testing of Technical Counter (R) Soil

  Insecticide (terbufos) in the Ames Test. Report No.

  AIR 5:419-431. Unpublished study prepared by American

  Cyanamid Co.
- 00085169 Kruger, R.; Feinman, H. 1973. 30-day Subacute Dermal Toxicity in Rabbits of AC-92100. Study No. 1611. Unpublished study prepared by FDRL and submitted by American Cyanamid.
- 00085172 Smith, J. M.; Kasner, J. A.; Wilson, N. H. (1972). A

Three Generation Reproduction Study of Pesticide AC 92,100 in Rats. Report No. 71R-727. Unpublished American Cyanamid Co. study prepared by Bio/Dynamics, Inc.

- 00087695 North, H. H. (1973). Counter Insecticide: Rat Metabolism of CL 92,100. Report No. 2-402. Unpublished study prepared by American Cyanamid Co.
- 00109446 Daly, I.; Rinehart, W.; Martin, A. (1979). A Three-Month Feeding Study of Counter terbufos Insecticide in Rats. Report No. 78-2343. Unpublished American Cyanamid Co. study prepared by Bio/Dynamics Inc.
- O0133296 Thilagar, A.; Kumaroo, P.; Kott, S. (1983). Chromosome Aberrations in Chinese Hamster Ovary Cells. Report No. T1906. 337006. Unpublished American Cyanamid Co. study prepared by Microbiological Associates, Inc.
- 00133297 Allen, J. S.; Johnson, E.; Fine, B. (1983).

  Mutagenicity Testing of AC 92,100 in the <u>in vitro</u>

  CHO/HGPRT Mutation Assay. Report No. 0402.

  Unpublished study prepared by American Cyanamid Co.
- O0133298 Godek, E.; Naismith, R.; Matthews, R. (1983). Rat
  Hepatocyte Primary Culture/DNA Repair Test. Report No.
  PH 311-AC-001-83. Unpublished American Cyanamid Co.
  study prepared by Pharmakon Research International,
  Inc.
- 00144805 Fisher, J. (1985). Rabbit Dermal  $LD_{50}$  (Intact Skin). Report No. A 85-54. Unpublished study prepared by American Cyanamid Co.
- 00147533 Rodwell, D. (1985). A teratology Study with AC 92,100 in Rats -Report No. WIL-35014. Unpublished study prepared by WIL Research Laboratories, Inc.
- 00161570 Putman, D. (1986). The Acute in vivo Cytogenetics
  Assay in Rats. Report No. T4277, 105002. Unpublished
  study prepared by Microbiological Associates Inc.
- 00161571 Mackenzie, K. (1986). Dominant Lethal Study with AC 92,100 in Rats: Final Report. Report No. 6123-137. Unpublished American Cyanamid Co. study prepared by Hazleton Laboratories America, Inc.
- 00161572 Shellenberger, T. (1986). One-Year Oral Toxicity Study

in Purebred Beagle Dogs with AC 92,100. Report No. 8414. Unpublished American Cyanamid Co. study prepared by Tegeris Laboratories, Inc.

- 00258710 Rusch, G. M.; Rinehart, W. E. (1980). A Two Week Inhalation Toxicity Study of Technical Counter terbufos in the Rat. Report No. 78-7168. Unpublished study prepared by Bio/dynamics Inc.
- 40098602 Daly, I. (1987). A One-Year Dietary Toxicity Study with AC 92,100 in Rats: Chronic Toxicity in Rats. Report No. 85-2964. Unpublished study prepared by Bio/Dynamics, Inc.
- 40098603 Shellenberger, T. (1986). Chronic Dietary Toxicity and Oncogenicity Study with AC 92,100 in Mice: Chronic Toxicity and Oncogenicity Mouse. Report No. 8422. Unpublished study prepared by Tegeris Laboratories, Inc.
- 40374701 Shellenberger, T.E. 1987. 28-Day Oral Toxicity Study in the Dog with AC 92,100. Study No. 87-021. Unpublished study conducted by Tegeris Laboratories. Also MRID 40374702.
- 40886301 Hoberman, A. (1988). A Developmental Toxicity Study (Embryo-Fetal Toxicity Teratogenicity) Study with AC 92-100 in Rabbits. Report No. 101-008. Unpublished study prepared by Argus Research Laboratories, Inc.
- Ioannou, M. (1995). Terbufos Toxicology Endpoint Selection Document. U. S. EPA Memorandum dated January 19.
- Levy, A.C. (1990). Terbufos (Counter 5G) State of Minnesota Request for Emergency Use for Control of Flea Beetles on Rape. U. S. EPA Memorandum dated February 9.
- Parkin, W. E. (1973). Request for Temporary Negligible Residue Tolerances for the Insecticide S-(tert-butylthio)-methyl-0,0-diethyl phosphorodithioate and its Cholinesterase Inhibiting Metabolites in or on Corn, Grain, Forage and Fodder at 0.05 ppm. U. S. EPA Memorandum dated February 6.

# TERBUFOS TOLERANCE SUMMARY

# APPENDIX A

Commodity	Current Tolerance (ppm)	Tolerance Reassessment (ppm)	Comment/Correct Commodity Definition
	Tolerances lis	ted under §180.352(a)	
Bananas	0.025	0.025	
Beets, sugar (roots)	0.05 (N)	0.05	The negligible residue designation (N) should be deleted.  Sugar beets (roots)
Beets, sugar (tops)	0.1	0.1	Sugar beets (tops)
Corn, field, fodder	0.5	0.5	
Corn, field, forage	0.5	0.5	
Corn, pop, fodder	0.5	0.5	
Corn, pop, forage	0.5	0.5	
Corn, grain	0.05 (N)	0.05	The tolerance for "Corn, grain" should be replaced with separate tolerances for Corn, field, grain
			and  Corn, pop, grain  The negligible residue  desígnation (N) should be  deleted.
Corn, sweet (K+CWHR)	0.05 (N)	0.05	The negligible residue designation (N) should be deleted.
Corn, sweet, forage	0.5	0.5	
Corn, sweet, fodder	0.5	0.5	
Sorghum, fodder	0.5	1.0	
Sorghum, forage	0.5	1.0	
Sorghum, grain	0.05	0.05	
	Tolerances i	isted under §180.352(b)	
Coffee beans, green	0.05	0.05	A proposal to extend the existing time-limited tolerance for an additional 2 years was issued in the FR [August 2, 1995; Volume 60, No. 148].

STATUS		EPA deterred UG/22/88 WHO reviewed 1989 RfD/PR reviewed 09/25/97	RfD/PR reviewed 05/22/96 RfD/PR reviewed 05/23/96	EFFECT OF ANTICIPATED RESIDUES		XRFD	75.83400	77 87400	77.01600	76.54800	75.58600	00077 02	76.80800	73.28000	85.41000	82.84000	77.0000	64.40000	75.29600	ያለ ፕ <b>ለ</b> 200	247.33800	51.59600	65.50800	167.12800	112.82200	72.39000	60.57800	57.93200	53.29600	
CADE / CABETTS		ling study itical. LEL= inhibition	); NOEL not	EFFECT OF A		ARC	0.000038	2,0000	0.000039	0.000038	0.000038	0 00004E	0.000038	0.000037	0.000043	0 000041	0.00039	0.000032	0.000038	870000	0.00048	0.000026	0.000033	0.000084	0.000056	0.000036	0,000030	0.000029	0.000027	
CATA CADE	No data gaps.	1-yr dog feeding study used as co-critical. LEL=	of plasma ChE); NOEL not established.	PICEOGRAPH	AS PERCENT	OF RFD	43.142000		42.180000	43.910000	42.652000		40.472000	750000	48.240000	000000	40.852000	37, 166000	40.194000	90070	144 172000	29.582000	39.458000	80.794000	68.364000	45,160000	36.508000	33.034000	28.652000	
	ADI UF>300	2 Z		•	NEW IMAC	OF RFD	152.640000		145.968000	150 574000	148.054000		133.888000	155 502000	160.882000		180.962000	152 002000	140.182000		142.826000	104 404000	120.556000	351 26000	247.160000	157.196000	131.464000	108.042000	97.452000	
	EFFECTS		No evidence of carcinog- enicity in rats or mice.		IMRC (MG/KG BODY WEIGHT/DAY)	NEW TMRC**	0.000076		0.000073	0.000078	0.000074	٠	0.000067	0.00000	0.000080		0.000000	0.000074	0.000020	1	0.000071	0.000199	0,00000	0.00000	0 00012	0.0000	0.000066	0.000054	0.000049	•
	EFF					RENT TMRC*	0.000055	1	0.000052	0.000056	0.000053		0.000047	0.000054	0.000056	:	0.000000	0.000052	0.000050		0.000051	0.000116	0.000037	0.000041	0.000.0	0.00005	0.00000	0.000038	0.000034	
	STUDY TYPE	28d feeding- dog NOEL= 0.0050 mg/kg 0.00 ppm			TOTAL	CURRE			NOS	NOS	NO.				•	•					6	R OLD)					CONTROLL GO CHAC TON	TAKES ON HONSING	NOT PREG. OR NURS)	
-	CHEMICAL INFORMATION	Terbufos Caswell #131A	A.1. CODE: 105001 CFR No. 180.352				POPULATION SUBGROUP	U.S. POPULATION - 40 STATES	U.S. POPULATION - SPRING SEASON	POPULATION -	U.S. POPULATION - FALL SEASON	LOLOUVI TON	NORTHEAST REGION	NORTH CENTRAL REGION	SOUTHERN REGION	ALCIENT SECTION	HISPANICS	NON-HISPANIC WHITES	NON-HISPANIC BLACKS		NURSING INFANTS (< 1 YEAR OLD)	NON-NURSING INFANTS (< 1 YEAR OLD)	FEMALES (13+ YEARS, PREGNANT)	FEMALES 13+ YEARS, NURSING	CHILDREN (1-6 YEARS OLD)	CHILDREN (7-12 TEAKS ULD)		MALES (13-17 TEAKS OLU, NO.	FEMALES (20 YEARS AND OLDER, NOT PREG. OR NURS)	

\*Current TMRC does not include new or pending tolerances.

	STATUS	HED reassess UV/23/71	LING TONIONE 1080	ath the reviewed 100/25/	Act of the reviewed 05/22/9	Act the reviewed 05/23/	KIU/FR IEVIEWS STEEL
DATE: 11/10/9/	DATA GAPS/COMMENTS	No data gaps.	1-yr dog feeding study	used as co-critical. Let-		E); NOEL NOT	established.
NUMBER 131A	DEFERENCE DOSES	Tinhition of plasma ChE.   ADI UF>300		EPA RfD= 0.000050		ţ	
AUTICIDATED RESIDUE INFORMATION FOR CASUELL NUMBER 131A	010000	Tickibition of plasma C		`	•	We evidence of carcinog-	U.OU DOM NO CONTROL OF MICE.
ANTICIPATED RESIDUE		STUDY TYPE	28d feeding- dog	NOEL = 0.0050 mg/ kg	mpd 00.00	LEL= 0.0150 mg/ kg	
	,	CHEMICAL	Terbufos	Caswell #131A	CAS No. 13071-79-9	A.1. CODE: 105001	CFR No. 180.352

reassess	deferred 06/22/88	PR reviewed	RfD/PR reviewed 05/22/96 RfD/PR reviewed 05/23/96		IN TAS RUN (ppm)	0 025000	0.022000	0.025000	0.025000	0.022000	0.02500	0.025000	0.025000	0.050000	0.050000	0.00000	0-006500	0.004500	0.004500	0.050000	0.050000	0.05000	0.00000	000000	000900	0.00900	0.006000	0.006000	0.00000	0.014500	0.014500	0.014500	0.014500	0.006000	0.200000	0.050000	0.05000	0.02000	0.05000	0.050000	
S I ROUGH	. ;	u,			X CROP TREATED	8	9.00	100.00	100.00	100.00	9.00	100.00	100.00	100.00	100.00	100.00	3.6 2.0	00.0	9.00	100.00	100.00	100.00	12.00	3.0	5.50 8.50	12.00	12.00	12.00	12.00	20.00	29.00	29.00	29.00	12.00	100.00	100.00	100.00	100.00	8.0	100.00	
No data gaps.	1-yr dog feeding study	used as co-critical. LEI	of plasma ChE); NOEL not	estabilished.	STATISTIC TYPE	4			4									•																							
REFERENCE DOSES	P Rf0=	R f0=			ANTICIPATED RESIDUE (ppm) AR		0.025000	0.022000	0.025000	0.025000	0.025000	0.025000	0.022000	0.05000	0.050000	0.050000	0.050000	0.05000	0.020000	0.05000	0.05000	0.05000	0.050000	0.050000	0.050000	0.05000	0.05000	0.050000	0.050000	0.050000	0.03000	0.05000	0.05000	0.050000	0.20000	0.050000	0.050000	0.050000	0.050000	0.05000	
TS R	<u> </u>		f carcinog-	ts or mice.	TOLERANCE (ppm)		P 0.025000	P 0.025000	P 0.025000	۵.	۵	۵	P 0.025000	2 0	. <	<	۵	۰	P 0.050000	. «	A 0.05000	•	۵	P 0.050000	P 0.050000	P 0.050000	0.02000	P 0.050000	9	0	P 0.050000	0.00000	P 0.050000	. 0	. «	<b>«</b>	<b>«</b>	<	A 0.050000	< <	•
EFFECTS	Inhibition of plasma cut.		No evidence of carcinog-	enicity in rats or mice	PET.#		6E3409	6E3409	6E34U9	6F3409	6E3409	6E3409	6E3409	6E34U9	•		6F1657	6F1657	6F1657	611057	416799	4F2996	6F1657	6F1657	6F1657	6F1657	751157 751657	6F1657	6F1657	1F2540	6F1657	0F 1637 4E1457	651657	KF1657	8H5549	2F2608	3F2926		2F2608	2F2608 2F2608	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
STUDY TYPE	ding- dog	NOEL = 0.0050 mg/kg 0.00 ppm	LEL= 0.0150	91	FOOD FORM		22 CONKED-FRESH-BAKED	10 RAW-FRESH OR NFS	21 COOKED-NFS	COOKED - FRESH	10 KAW-FRESH OK NES		23 COOKED-FRESH-BOILED	25 COOKED-FRESH-FRIED	21 COOKED-NFS	11 RAW-FRESH-PICKLED, CORMED, ON CORED	Z1 COOKED-NES	10 RAW-FRESH OR WFS	21 COOKED-NFS		10 RAW-FRESH OR NFS	21 COOKED-MFS	10 DAU-FRESH OR WES		22 COOKED-FRESH-BAKED			10 KAW-FKESH UK NFS	22 COOKED-FRESH-BAKED				22 COOKED-FRESH-BAKEU		18 PROCESSED UIL	PROCESSED			10 RAW-FRESH OR NFS	21 COOKED-NFS	23 COOKED-TRESH-BOILED
CHEMICAI		Caswell #131A	A.1. CODE: 105001	CFR No. 180.332	60		COCONIC CAMARAC	DANAMAS-UNSTED	BANANAS-FRESH	BANANAS-FRESH	BANANAS-DRIED	BANANAS-UKIEU	PLANTAINS	PLANTAINS	COFFEE	MUSTARD SEED	MUSTARD SEED	CORN, SUFET	CORN, SWEET	CORN, SWEET	PEANUTS-WHOLE	PEANUTS-WHOLE	PEANUTS-WHOLE	CORN, GRAIN-ENDO	CORN. GRAIN-ENDO	CORN, GRAIN-ENDO	CORN, GRAIN-BRAN	CORN SUGAR		SORGHUM				BEET SUGAR	CORN, GRAIN-UIL	SOVREANS-011	RAPE SEED	SOYBEANS-UNSPEC.	SOYBEANS-DRY	SOYBEANS-DRY	SUTBEANS-UKT
	Terbufos					FOOD CODE		06002AA	06002AB	06002AB	06002DA	06002DA	06016AA	06016AA	07002AA	08028AA	08028AA	15005AA	15005AA	15005AA	15006AA	15006AA	15006AA	24002EA	24002EA	24002EA	24002HA	24002SA	24.0025A	24006AA	25002SA	25002SA	25002sA	25002SA	270020A	2701004	27017AA	28023AA	28023AB	28023AB	28023AB

PAGE: 2	STATUS HED reassess 09/25/97 EPA deferred 06/22/88 WHO reviewed 1989 RfD/PR reviewed 05/22/96 RfD/PR reviewed 05/22/96 RfD/PR reviewed 05/23/96	Special sections
DATE: 11/18/97	No data gaps.  1-yr dog feeding study used as co-critical. LEL= 0.015 mg/kg (inhibition of plasma ChE); NOEL not established.	
UE INFORMATION FOR CASUELL NUMBER 131A	reference DOSES  Inhibition of plasma ChE. ADI UF>300 OPP RfD= 0.000050 EPA RfD= 0.000050 No evidence of carcinog- enicity in rats or mice.	
ANTICIPATED RESIDUE	STUDY TYPE  28d feeding- dog  NOEL= 0.0050 mg/kg  0.00 ppm  LEL= 0.0150 mg/kg  0.00 ppm  ONCO: E (RfD/PR Committee)	
	CHEMICAL ufos Caswell #131A CAS No. 13071-79-9 A.I. CODE: 105001 CFR No. 180.352	

WHO reviewed 1989 RfD/PR reviewed 09/25/97	RfD/PR reviewed U3/22/90 RfD/PR reviewed U5/23/96	RES. VALUE USED IN TAS RUN (PPM)	0.050000 0.050000 0.050000 0.050000 0.050000 0.050000 0.050000
		% CROP TREATED	100.00 100.00 100.00 100.00 100.00 100.00 100.00
used as co-critical. LEL=	of plasma ChE); NOEL not established.	AR STATISTIC TYPE	
OPP Rf0= 0.000050 EPA Rf0= 0.000050		ANTICIPATED RESIDUE (ppm) AR	0.05000 0.05000 0.05000 0.05000 0.05000 0.05000 0.05000 0.05000
	No evidence of carcinog- enicity in rats or mice.	TOLERANCE PET.# (ppm)	ZF2608 A 0.050000
NOEL = 0.0050 mg/kg	LEL= 0.0150 mg/kg 0.00 ppm 0.00 curo. c /P40/PP Committee)	FOOD FORM	25 COOKED-FRESH-FRIED 31 COOKED-FRESH OR CANNED 21 COOKED-NFS 22 COOKED-FRESH-BAKED 31 COOKED-FRESH-BAKED 21 COOKED-FRESH OR CANNED 21 COOKED-NFS 21 COOKED-NFS 22 COOKED-NFS 23 COOKED-FRESH-BAKED 53 COOKED-CANNED-BOILED
Terbutos Caswell #131A CAS No. 13071-79-9	A.1. CODE: 105001 CFR No. 180.352	000 CODE FOOD	SOYBEANS-DRY 25 SOYBEANS-DRY 31 SOY-FL, FULL FAT 21 SOY-FL, FULL FAT 22 SOY-FL, FULL FAT 31 SOY-FL, LOW FAT 21 SOY-FL, DEFAT 22 SOY-FL, DEFAT 23
Terbutos Caswell #131 CAS No. 1307	A.1. CODE: 1 CFR No. 180.	F000 C00E F000	280234B SOYBEANS-DI 280234B SOYBEANS-DI 280234A SOY-FL, FUI 280234A SOY-FL, FUI 280234A SOY-FL, FUI 280234C SOY-FL, DEFI 280234C SOY-FL, DEFI 280234C SOY-FL, DEFI 280234C SOY-FL, DEFI 280234C SOY-FL, DEFI 280234C SOY-FL, DEFI

DATE: 10/27/97

#### TOLERANCE ASSESSMENT SUMMARY FOR Terbufos USING ANTICIPATED RESIDUES CASWELL #131A

ANALYSIS FOR POPULATION SUB-GROUP: U.S. POPULATION - 48 STATES

EXISTING ANTICIPATED RESIDUES (PUBLISHED ONLY)

RESULT IN AN ARC OF:

0.000016 MG/KG/DAY 32,686 % OF THE ADI.

THE EXISTING ARC IS EQUIVALENT TO:

NO NEW ANTICIPATED RESIDUES ARE IN THE FILE.

OTHER PENDING ANTICIPATED RESIDUES EXCLUDING THE

CURRENT NEW PETITION HAVE AN ARC OF:

0.000022 MG/KG/DAY

THIS ARC WILL OCCUPY 43.148

IF ALL PENDING ANTICIPATED RESIDUES (INCLUDING THE

CURRENT NEW PETITION) ARE GRANTED THE RESULTANT ARC WILL BE:

0.000038 MG/KG/DAY

THE TOTAL ARC WILL OCCUPY

75.834 % OF THE ADI.

ANALYSIS FOR POPULATION SUB-GROUP: NURSING INFANTS (< 1 YEAR OLD)

EXISTING ANTICIPATED RESIDUES (PUBLISHED ONLY)

RESULT IN AN ARC OF:

THE EXISTING ARC IS EQUIVALENT TO:

0.000027 MG/KG/DAY

% OF THE ADI.

2 OF THE ADI. X Z = 164 % 54.566

NO NEW ANTICIPATED RESIDUES ARE IN THE FILE.

OTHER PENDING ANTICIPATED RESIDUES EXCLUDING THE

CURRENT NEW PETITION HAVE AN ARC OF:

0.000020 MG/KG/DAY

40.796

% OF THE ADI. ×3 = 122%

IF ALL PENDING ANTICIPATED RESIDUES (INCLUDING THE

CURRENT NEW PETITION) ARE GRANTED

THE RESULTANT ARC WILL BE: 95.362

THE TOTAL ARC WILL OCCUPY

THIS ARC WILL OCCUPY

0.000048 MG/KG/DAY

\* OF THE ADI. X 3 = 286 %

ANALYSIS FOR POPULATION SUB-GROUP: NON-NURSING INFANTS (< 1 YEAR OLD)

THE TOTAL ARC WILL OCCUPY

EXISTING ANTICIPATED RESIDUES (PUBLISHED ONLY)

RESULT IN AN ARC OF:

THE EXISTING ARC IS EQUIVALENT TO:

0.000040 MG/KG/DAY 80.966

2 OF THE ADI. x Z = 243%

NO NEW ANTICIPATED RESIDUES ARE IN THE FILE.

OTHER PENDING ANTICIPATED RESIDUES EXCLUDING THE

CURRENT NEW PETITION HAVE AN ARC OF: THIS ARC WILL OCCUPY

0.000083 166.372 \* OF THE ADI. + 3 = 499%

IF ALL PENDING ANTICIPATED RESIDUES (INCLUDING THE

CURRENT NEW PETITION) ARE GRANTED

THE RESULTANT ARC WILL BE:

0.000124 247.338

MG/KG/DAY

2 OF THE ADI. +3 = 742%

TOLERANCE ASSESSMENT SUMMARY FOR Terbufos USING ANTICIPATED RESIDUES CASWELL #131A

ANALYSIS FOR POPULATION SUB-GROUP: CHILDREN (1-6 YEARS OLD)

EXISTING ANTICIPATED RESIDUES (PUBLISHED ONLY.)

RESULT IN AN ARC OF: THE EXISTING ARC IS EQUIVALENT TO: 0.000039

x = 232%77.332

NO NEW ANTICIPATED RESIDUES ARE IN THE FILE.

OTHER PENDING ANTICIPATED RESIDUES EXCLUDING THE

CURRENT NEW PETITION HAVE AN ARC OF:

0.000045 MG/KG/DAY MG/KG/DAY 269 % 89.796

IF ALL PENDING ANTICIPATED RESIDUES (INCLUDING THE

CURRENT NEW PETITION) ARE GRANTED

THE RESULTANT ARC WILL BE: 0.000084

THE TOTAL ARC WILL OCCUPY

MG/KG/DAY 167.128

\* OF THE ADI. Y 3 = 501%

ANALYSIS FOR POPULATION SUB-GROUP: CHILDREN (7-12 YEARS OLD)

THIS ARC WILL OCCUPY

THIS ARC WILL OCCUPY

EXISTING ANTICIPATED RESIDUES (PUBLISHED ONLY)

RESULT IN AN ARC OF: THE EXISTING ARC IS EQUIVALENT TO: 0.000022 MG/KG/DAY \* OF THE ADI. \$3 = 133% 44.460

NO NEW ANTICIPATED RESIDUES ARE IN THE FILE.

OTHER PENDING ANTICIPATED RESIDUES EXCLUDING THE

CURRENT NEW PETITION HAVE AN ARC OF:

MG/KG/DAY 7 = 205% 0.000034 68.362

IF ALL PENDING ANTICIPATED RESIDUES (INCLUDING THE

CURRENT NEW PETITION) ARE GRANTED

THE RESULTANT ARC WILL BE:

THE TOTAL ARC WILL OCCUPY

0.000056 112.822

MG/KG/DAY  $\star$  OF THE ADI.  $\star$  3 = 338%

S	
2	
Dietary	
Acute	
Terbufos	
for	
Coffee	
Excluding	
Uses	
Published	

DETAILED ACUTE ANALYSIS: ALL	ILY CONSUMPT	,
*CASWELL NO: 131A CFR NO: CFR180 *CAS NO: 13071-79-9 SHAUGHNESSY NO: *STATUS CODES: *RDV INFO: The LD value used in th	105001 B 105001 B c c c c c c c c c c c c c c c c c c c	
**************************************	ESTIMATED % OF POTENTIAL MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	
ESTIMATES BASED ON PRIOR TOLERANCES: NEW TOLERANCES:	PERSON DAYS THAT ARE USER-DAYS MG/KG BODY WEIGHT/DAY AS PERCENT OF RDV 99.20 99.20 0.000052 10.34 99.20 estimated % of Population user-days with residue contribution exce eding x times the RDV, for x= 0.2.4.6.8 1 1.2 1.4 1.6 1.8 2 3 4 5 10 15 20	6 1 1/1 1/1 1/1 E.
PRIOR TOLERANCES: NEW TOLERANCES:	100 14 4 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
MOE = $0.005$ mg/kg/day $\div 0.0005$ mg/kg/day	05  mg/kg/day = 10	
INFANTS(<1 YEAR)	ESTIMATED X OF POTENTIAL MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	
ESTIMATES BASED ON PRIOR TOLERANCES: NEW TOLERANCES:	PERSON DAYS THAT ARE USER-DAYS MG/KG BODY WEIGHT/DAY AS PERCENT OF RDV 72.61 72.61 72.61 72.61 6.000138 27.52 27.52 ESTIMATED % OF POPULATION USER-DAYS WITH RESIDUE CONTRIBUTION EXCE EDING X TIMES THE RDV, FOR X= 0 .2 .4 .6 .8 1 1.2 1.4 1.6 1.8 2 3 4 5 10 15 20	
PRIOR TOLERANCES: NEW TOLERANCES:	100 42 23 14 7 4, 2 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 100 100	Mean
NOE = 0.005 mg/kg/day ÷ 0.001 mg/kg/day	1  mg/kg/day = 5	
CHILDREN(1-6 YRS)	ESTIMATED % OF POTENTIAL MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	
ESTIMATES BASED ON PRIOR TOLERANCES: NEW TOLERANCES:	PERSON DAYS THAT ARE USER-DAYS MG/KG BODY WEIGHT/DAY AS PERCENT OF RDV 99.77 99.77 99.77 0.000131 26.16 99.77 ESTIMATED % OF POPULATION USER-DAYS WITH RESIDUE CONTRIBUTION EXCE EDING X TIMES THE RDV, FOR X= 0 .2 .4 .6 .8 1 1.2 1.4 1.6 1.8 2 3 4 5 10 15 20	
PRIOR TOLERANCES: NEW TOLERANCES:	100 47 20 9 4 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
MOE = $0.005$ mg/kg/day $\div 0.0008$ mg/kg/day	08  mg/kg/day = 6	

2 two hotte

57

*	* *	*	*	*	* *
****	OC. NO.				******
ETALLED BRITT ANALYSIS: ALL STATISTICS BASED ON USERS: DAILY CONSUMPTION	SF STUDY TYPE SPECIES EFF. LEV. CORE GRADE DOC. NO.*				is is 0.0005 MG/Ku of Boor Welchillori PS APPROVED: Bata NOT Used PUBLISHED Data Used
コルコニコンス ここのはななななななななななななななななななななななななななななななななななな	EFF. LEV.				.d.
<u>^</u>	SPECIES			>	): Data Use
***	TUDY TYPE	4.	.•	A LICTORY	PUBL I SHED
PTION	SF S	000100		, (C)	or bou
ILY CONSUM	NOEL	4			/ED:Bata N
USERS! DAI	**************************************	1000.0000		,	is 0.0003 APPRO
S BASED ON	**************************************	CFR NO: CFR180,352 A 00000.0001	105001 B	U	*RDV INFO: The LD value used in this analysis is 0.0005 MG/KG of BOD! WELLINION. APPROVED: Data Used #511F INFO: NFU ACTION: No User Modifications APPROVED: Data Used #511F INFO: NFU ACTION: No User Modifications
STATISTIC	******	40: CFR180.	*CAS NO. 13071-79-9 SHAUGHNESSY NO: 105001 B		used in thi
ALYSIS: ALI	*****		9-9 SHAUGH		LD value
ACHTE AND	*******	*MAME: LEKBUTUS	13071-7	s cooes:	NFO: The
etali En		TWANE:	ACAS M	*CTATU	*RDV 11

•		÷ 5	<
* * * * *		50	00
*		* <del>*</del> * * * * * * * * * * * * * * * * *	00
**	• .	15 THAT ARE USER-DAYS MG/KG BODY WEIGHT/DAY AS PERCENT OF RDV 99.32 6.70 99.32 0.000034 6.70 99.32 X OF POPULATION USER-DAYS WITH RESIDUE CONTRIBUTION EXCE EDING X TIMES THE RDV, FOR X= 2 .4 .6 .8 1 1.2 1.4 1.6 1.8 2 3 4 5 10 15	00
**		新. 8	00
4 4 4	DAY	RDV TIMES	00
**************************************	USER-	6.70 6.70 6.70 EDING X	00
Y WEIGHT/DAY PUBLISHED: Data Used	MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	AS PERCENT OF RDV 6.70 6.70 6.70 EXCE EDING X TIMES 2 3 4	0.0
/DAY HED: Da	TR.IBUT.	1.8	00
0.0001 0.0001 000100 MG/KG of BODY WEIGHT/DAY APPROVED: Data NOT Used' PUBLISHED:	NE CON.	T/DAY ONTRIB	00
00 BODY	RESID	80DY WEIGH 0.000034 0.000034 RESIDUE C	00
000100 KG of B	DAILY	MG/KG BODY WEIGHT/DAY 0.000034 0.000034 S WITH RESIDUE CONTRIE 1 1.2 1.4 1.6	00
MG/	MEAN	MG/K AYS VI	00
005 ROVED:		DAYS USER-D	00
900 s: **	ITIAL	USER-ATION .6	0 0
A 00 F	: POTE)	1AT ARE 32 32 POPUL	
.352 105001 105001 11 ficat	,	99.32 99.32 99.32 0 % 0F PC	9 9
CFR NO: CFR180.352 IAUGHNESSY NO: 10500 slue used in this and ion: No User Modifica	ESTIMATED X OF POTENTIAL	PERSON DAYS THAT ARE USER-DAYS 99.32 99.32 ESTIMATED X OF POPULATION USER- 0 .2 .4 .6 .8	100
ACT I	(S)	ESTIMATES BASED ON PRIOR TOLERANCES: NEW TOLERANCES:	PRIOR TOLERANCES: NEW TOLERANCES:
*MAME: TERBUFOS *CASWELL NO: 131A *CAS NO: 13071-79- *STATUS CODES: *RDV INFO: The LC *FILE INFO: NEW	FEMALES(13+ YRS)	ESTIMAT PRI N	a a a

			8	00
			* <del>X</del> 2	00
			DV, FOR	00
			3 E	00
	-DAY	F ROV	TIMES	00.
	V USER	2.70 7.70	N S S	00
	MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	AS PERCENT OF RDV 7.70	EXCE EL	00
	TRIBUT		1.8 1.8	00
	, NO 3	MG/KG BODY WEIGHT/DAY	ULUNUSS WITH RESIDUE CONTRIBUTION E	00
	RESID	VE 1GH 0038		00
	DAILY	6 BODY 0.00	0.00 TH RES 1.2	00
	MEAN	MG/K	VS W	00
		AYS	JSER-D/	00
	14	USER-I	MOIT!	00
	POTENI	T ARE	POPULA .4	
ry = 17	X 0F	VS THAT	99.80 2. of p	ဆေ
3 mg/kg/day = 17	ESTIMATED % OF POTENTIAL	PERSON DAYS THAT ARE USER-DAYS 99.80	99.80 U. OUDUSE CONTRIBUTION EXCE EDING X TIMES THE RDV, FOR X= ESTIMATED X OF POPULATION USER-DAYS WITH RESIDUE CONTRIBUTION EXCE EDING X TIMES THE RDV, FOR X= 0 .2 .4 .6 .8 1 1.2 1.4 1.6 1.8 2 3 4 5 10 15	00 00 1
MOE = $0.005 \text{ mg/kg/day} \div 0.0003 \text{ i}$	MALES(13+ YRS)	ESTIMATES BASED ON PRIOR TOLERANCES:	NEW TOLERANCES:	PRIOR TOLERANCES: NEW TOLERANCES:
#0E	MALE		0	

July July

n
ŝ
-
3
3
_
ಲ
-
-
5
-
er.
-
•
➣
MIBLYSIS
=
•
4
_
Acute
Ų
⋖
515
=
₣
∍
Coffee
ç
•
-

TUDY RDV NDEL SF SIUDY HTPE SPECIES CITY A 00000.0001  A 00000.0001  B  C  C  A 00000.0001  MG/KG of BODY WEIGHT/DAY  FISS is 0.0001  A PPROVED:Data NOT Used PUBLISHED: Data Used	*	ا ج	0.0			; 20	00			20	00	
*			•								00	•
*		×~	00		*	FOR X±	00			FOR X=		
**		v, FOR 10	00	•		RDV, F	00			RDV,	0.0	
* **		THE ROV	0			THE RE	00			五 元 2	00	
在在在在在在在在在在在在在在在在在在在在在在在在在在在上上,	¥	RDV	00	-	ΑΥ	RDV TIMES	00		DAY	RDV TIMES	00	
* *	SER-D	o ×	00		SER-C	ŏ. ×	00		ISER-I	p ×	00	
Data Used	ER U	5.2 5.2 5.2 EDIN			PER U	PERCENT 0.00 0.00 E EDING 2 3			PER L	Z		
	8	AS PE EXCE 2	00		NO	AS PE	00		101 T	1 '	00	
SHED: D	RIBUT	1.8 8.1	0.0		RIBUT		00	,	RIBU	11.0N	00	
PUBLISHED: Data Used	MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	<b>2</b>	00		MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	HT/DAY CONTRIBUTION 1.6 1.8	00		MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	HT/DAY CONTRIBUTION 1.6 1.8	00	
	TONE	177	00		SIDUE	117	00	•	SIDUE	10	00	
* * *	Y RES	800Y WE10 0.000005 0.000005 RESIDUE			¥.	BODY WEI 0.000000 0.000000 RESIDUE			.≺ RE	BODY WEI 0.000008 0.000008 RESIDUE		
01 Used	DAIL	G 800 0.0 0.0 1.2	00	· · · · ·	DAIL	6 B00 0.0 1.2	00		DAI	1.2	00	
MG/KG of D:Data NOT Used	MEAN	MG/KG	0.0		MEAN	MG/KG	00		MEAN	MG/KG	00	
_ <u>₩</u> *		DAYS MG/KG BODY VEIL 0.000005 0.000005 0.000005 USER-DAYS WITH RESIDUE .8 1 1.2 1.4	00			THAT ARE USER-DAYS MG/KG BODY WEIG 0.00 0.00 0.00 OF POPULATION USER-DAYS WITH RESIDUE .4 .6 .8 1 1.2 1.4	00			TARE USER-DAYS MG/KG BODY WEIL  4. 0.000008 POPULATION USER-DAYS WITH RESIDUE  4. 6.8 1 1.2 1.4	00	
0.0001 APPROV		ARE USER-DAYS PULATION USER 4 .6 .8				THAT ARE USER-DAYS 0.00 0.00 0F POPULATION USER	00			1HAT ARE USER-DAYS 0.74 0.74 0F POPULATION USER 4 .6 .8	00	
, #	NTIAL	E USET LATIO	00		NTIAL	E USEI LATIO			NTIA	IE USI		
B C /sis ions	POTE		00	125	POTE	THAT AR 0.00 0.00 0F POPU	0.0		% OF POTENTIAL	THAT AF 0.74 0.74 0F POPU	00	
s analy ificat	% OF	DAYS THAT 44.31 44.31 ED % OF PO		Ħ	% OF	S 0.5	00		% OF	ی بدی	S	-
this Modif	ESTIMATED % OF POTENTIAL	N DAY	001	/kg/day	ESTIMATED % OF POTENTIAL	N DAYS	00	,	AATED		9 9 9 1 9	
CFK NO: LFK 100.552 AUGHNESSY NO: 1056 I'ue used in this al ON: No User Modifi	ESTIP	PERSON DAY	٦	)4. mg/	ESTI	PERSON ESTIMAT			ESTIMAT	PERSON ESTIMAT 0		
*CASMELL NO: 13071-79-9 SHAUGHWESSY NO: 105001 B *CAS NO: 13071-79-9 SHAUGHWESSY NO: 0 C *STATUS CODES: *REDV INFO: The LD value used in this analysis i *FILE INFO: NEW ACTION: No User Modifications ************************************		_ :: :: _ :: ::	ES:	= $0.005 \text{ mg/kg/day} \div 0.00004 \text{ mg/kg}$		:: :: ::::::::::::::::::::::::::::::::	ES:			CES:	CES:	
Valu	!	ESTIMATES BASED ON PRIOR TOLERANCES: NEW TOLERANCES:	PRIOR TOLERANCES: NEW TOLERANCES:	+ 46	:	ESTIMATES BASED ON PRIOR TOLERANCES: NEW TOLERANCES:	PRIOR TOLERANCES: NEW TOLERANCES:	*	:	BASED ON TOLERANCES: TOLERANCES:	PRIOR TOLERANCES: NEW TOLERANCES:	
L LD	TATES	S 88. W TOI	5 3 0 10 10 10	kg/d		S BAS TOI	₹.¥ 1010		(2)		10R TO NEW TO	
13071 00ES: 17 17	-48 STATES	PR 10	PR TO	/gw 5	YEAR	PRIOR NEW	PR 10 NE		-6 YR	ESTIMATES PRIOR NEW	PR 10	
NO: 1 NO: 1 US CC INFO:	06	ESTI		0.00	S(<1	EST		<b>XX</b> =	ENC1	EST		
*CASWELL NO: 131A *CAS NO: 13071-79-9 *STATUS CODES: *ROV INFO: THE LD *FILE INFO: NEW AC	U.S. POP 48 STATES			30	INFANTS(<1 YEAR)			11 30 81	CHILDREN(1-6 YRS)			
	<u> </u>	0		Ī	=	0	47944		ပ	0		

ETAILED ACLIE ANALYSIS: ALL STATISTICS BASED ON USERS' DAILY CONSUMPTION ************************************	MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	EIGHT/DAY AS PERCENT OF RDV 05 5.48 05 5.48 05 05 6.48 06 07 07 08 08 09 09 09 09 09 09 09 09 09 09 09 09 09			MEAN DAILY RESIDUE CONTRIBUTION PER USER-DAY	EIGHT/DAY AS PERCENT OF RDV 05 4.86 05 4.86 05 4.86 06 CONTRIBUTION EXCE EDING X TIMES THE RDV, FOR X= 06 CONTRIBUTION EXCE EDING X TIMES THE RDV, FOR X= 07 1.6 1.8 2 3 4 5 10 15 20	
S' DAILY CONSUMPTION ************************************	MEAN DAILY RESIDUE		0 0 0		MEAN DAILY RESIDUE	MG/KG BODY WEIGHT/DAY 0.000005 0.000005 15 WITH RESIDUE CONTRI	0 0 0
S: ALL STATISTICS BASED ON USERS' DAILY CONSUMPTION ************************************	ESTIMATED % OF POTENTIAL	PERSON DAYS THAT ARE USER-DAYS WG/KG BODY WEIG 57.33 0.000005 57.33 0.000005 ESTIMATED % OF POPULATION USER-DAYS WITH RESIDUE 0 .2 .4 .6 .8 1 1.2 1.4	100 2 0 0 0 100 100 2 0 0 0	4  mg/kg/day = 125	ESTIMATED % OF POTENTIAL	PERSON DAYS THAT ARE USER-DAYS MG/KG BODY VEIG 55.30 0.000005 55.30 0.0000005 ESTIMATED % OF POPULATION USER-DAYS WITH RESIDUE 0 .2 .4 .6 .8 1 1.2 1.4	100 1 0 0 0
DETAILED ACLIE ANALYSIS: ALL STATISTIC ************************************	FEMALES(13+ YRS)	ESTIMATES BASED ON F PRIOR TOLERANCES: NEW TOLERANCES:	PRIOR TOLERANCES: NEW TOLERANCES:	NOE = $0.005 \text{ mg/kg/day} \div 0.00004 \text{ mg/kg/}$	MALES(13+ YRS)	ESTIMATES BASED ON P PRIOR TOLERANCES: NEW TOLERANCES: 0	PRIOR TOLERANCES:

MOE =  $0.005 \text{ mg/kg/day} \div 0.00004 \text{ mg/kg/day} = 125$